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Systemic lupus erythematosus
Clinical features
SLE is a typical systemic autoimmune disease characterised by widespread involve-
ment of organs including serosa, joints, central nervous system, skin and kidneys. The
incidence of SLE varies between geographic areas, genders and ages. Women during
their childbearing years and black Americans and Hispanics have the highest inciden-
ce. The incidence for northern Europe is about 40 per 100,000 1;2. Diagnostic criteria for
SLE are based on the classification criteria for SLE introduced by the American College
of Rheumatologists. Although these criteria were meant for research purposes, to cate-
gorise patients for clinical trials, they are also used in clinical practise. On the bases of
these clinical trials new drug therapies were developed for treatment of the disease
and for supportive care. With the introduction of steroids and cytotoxic agents the 5-
year survival rate of patients with SLE dramatically increased from 50 % in the fifties
to over 90 % in the nineties 3;4. However, with the improved results for treatment of
active disease after introduction of aggressive immunosuppressive drugs, undesirable
side effects became also more apparent. Therefore, treatment of a patient with SLE is
a challenging quest for every doctor working in this field.  
Pathogenesis
Multiple factors are involved in the pathogenesis of SLE i.e., genetic, immunological,
hormonal, viral and environmental factors. The precise aetiology of SLE, however, is
unknown. An important role for genetic predisposition is suggested by the concor-
dance of SLE in identical twins (20-50%) and dizygotic twins (5%) 5. Many different
genes have been demonstrated to contribute to disease susceptibility. However, in
some patients a single gene may be responsible, as been reported for homozygous
deficiency of C1q, the first component of the classical pathway of complement activa-
tion 6.
Numerous immunologic abnormalities have been distinguished in patients with SLE,
all concerning immune dysregulation related to loss of self-tolerance, as characterized
by B cell hyperactivity, autoantibody production, and immune complex formation 7.
The central immunological disturbance in patients with SLE is autoantibody produc-
tion. Autoantibodies against a variety of self-antigens can be detected in sera of
patients with SLE. An important group of autoantibodies is directed against nucleoso-
mes and their different elements. Anti-nuclear antibodies occur in more than 95 per-
cent of SLE patients and anti-dsDNA antibodies are the characteristic autoantibodies
found in patients with SLE 8. Specific autoantibodies in serum from patients with SLE
are associated with certain disease characteristics. Anti-SSA and anti-SSB antibodies
are associated with cardiac involvement in SLE and anti-cardiolipin antibodies are
associated with thrombotic events, whereas anti-DNA and anti-C1q antibodies are
associated with lupus nephritis 9-14. In patients with SLE antibodies directed against
other components of the complement system have also been reported (Table 1). The cli-
nical significance of these autoantibodies, however, is not always clear. Furthermore,
most of these autoantibodies are also found in sera from patients with other diseases 
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Antibody Disease association References
Anti-C1q SLE 12
Hypocomplementaemic urticarial
vasculitis syndrome
122
Felty’s syndrome 123
Rheumatoid arthritis 
Rheumatoid vasculitis 123
Classic polyarthritis nodosa 123
Sjögren’s syndrome 124
Mixed connective tissue disease 123
Polychondritis 123
Temporal artritis 123
Mixed cryoglobulinaemia 123
Glomerulonephritis 123;125-127
Anti-C1s SLE 128
Anti-MBL SLE 129
Anti-C4 SLE 130
C3NeF SLE 131
Post streptococcal
glomerulonephritis 
MPGN
Partial lipodystrophy
132
133
134
Immunoconglutinins SLE 135
Rheumatoid arthritis 
PNH
Chronic liver disease
135
136
137
Anti-CR1 SLE 138
Colitis 
Liver cirrhosis 
139
140
Anti-Calreticulin SLE 141
Multiple sclerosis 
Sjogrens Syndrome
Primary billiary cirrhosis 
Coeliac disease
Congenital heart block
142
143
144
145
146
Table 1. Autoantibodies against complement components, convertases, complement
receptors and complement regulatory proteins in patients with SLE
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than SLE and the presence of some of these autoantibodies has been reported in healt-
hy individuals 15. It has recently been suggested that autoantibodies are present and
accumulate many years before patients develop the clinical characteristics of SLE16.
Therefore, apparently healthy individuals with circulating autoantibodies might deve-
lop the clinical characteristics of SLE later on. 
Lupus nephritis and the role of autoantibodies and complement 
Lupus nephritis (LN) is a frequent complication of SLE with major influence on mor-
bidity and mortality 17;18. In contrast to the female predominance in acquiring SLE the
incidence of renal disease for patients with SLE is equal between males and females 19
The incidence of LN is higher in younger patients and those from African-American
origin 19;20. Although treatment of lupus nephritis with new immune-suppressive drugs
has improved renal outcome, progression towards end-stage renal disease is still an
important complication for patients with LN. For diagnostic, therapeutic and prognos-
tic purposes the pathology of lupus nephritis has been classified according to the cri-
teria of the Word Health Organisation (WHO). Recently a revised version of the WHO
lupus nephritis classification has been developed to improve treatment strategy and
research quality in LN 21. One of the important criteria for the histological diagnosis of
LN is the presence of antibodies and complement assessed by immunofluorescent stai-
ning of renal biopsies.
The original model proposed to explain the presence of autoantibodies and comple-
ment deposited in inflammatory lesions in glomeruli of patients with SLE and renal
involvement, was that immune complexes consisting of autoantigens and autoantibo-
dies activate complement and their subsequent deposition in renal tissue causes local
inflammatory injury. Patients with SLE and lupus nephritis show decreased serum
complement levels of the classical and the alternative pathway during active phases of
disease which is associated with organ damage 22-24. Both anti-DNA and anti-C1q anti-
bodies are present in renal tissue demonstrated by elution of these antibodies from
kidneys from patients with lupus nephritis 25-27. Increased serum levels of both anti-
DNA and anti-C1q autoantibodies are present in patients with lupus nephritis and a
rise of serum levels of these autoantibodies can predict a flare of disease activity 28;29. A
rise in anti-DNA antibodies is most sensitive for predicting all kinds of disease exacer-
bations, whereas a rise in anti-C1q has the highest specificity for predicting a renal
relapse 28. A potentially pathogenic mechanism for renal injury by anti-C1q antibodies
has been suggested by showing stabilization of deposited C1q in renal capillaries by
anti-C1q antibodies 30. Recently it has been demonstrated that deposition of IgG in the
kidney is essential for C1q deposition and subsequent binding of anti-C1q antibodies.
Enhanced activation of neutrophils triggered by binding of the Fc-fragments from IgG
augmented by the presence of anti-C1q antibodies and activation of the complement
system, leads to tissue damage 31.
Besides a detrimental role of complement in the effector-phase of the disease, when
locally activated, increasing evidence is presented of an protective role of complement
in the induction-phase of the disease. As mentioned above autoantibodies are present
in the induction phase, before clinical onset, of the disease. Different hypotheses for
linking complement to the generation of autoantibodies are currently under investiga-
tion. One of the hypotheses proposes that complement plays a role in determining the
threshold of activation of B and T lymphocytes and that complement deficiency cau-
ses autoantibody production and subsequently tissue damage by impairing the nor-
mal mechanism of tolerance induction and maintenance 32. Another hypothesis invol-
ves the role of complement in physiological waste-disposal mechanisms, in particular
the clearance of dying cells and immune complexes. Complement deficiency has the-
refore been suggested to impair normal mechanisms of waste disposal and conse-
quently this material can be a source of autoantigens 33;34. C1q has been shown to bind
to late apoptotic material and to play an important role in their clearance via C1q
receptors present on cells of the mononuclearphagocyte system 35;36. The important role
of C1q has been most clearly shown in studies with C1q-deficient mice 37. These mice
develop a proliferative glomerulonephritis characterized by the presence of apoptotic
cells. Not only C1q has been shown to be involved in uptake of apoptotic cells, this has
also been demonstrated for MBL and other molecules that can activate the comple-
ment system, such as human C-reactive protein (CRP) and IgM 36;38-40. In patients with
SLE, defective uptake of apoptotic cells, for other reasons than C1q deficiency, might
trigger an autoimmune response against C1q leading to production of anti-C1q auto-
antibodies. Hypothetically a similar mechanism of defective uptake of apoptotic cells
might generate other autoantibodies directed against proteins playing a role in clea-
rance of apoptotic material, such as antibodies directed against MBL.
The Complement system
Pathways of complement activation
The complement system is a major constituent of the innate immune defence system
and is involved in initiation of adaptive immunity 22;23. Activation of different comple-
ment components in an enzymatic cascade reveals three different pathways of comple-
ment activation, the classical pathway, the alternative pathway and the lectin pathway,
each with its own recognition mechanism. These pathways converge at the central
component of the complement system, C3. The final common pathway leads to the for-
mation of a protein complex on a complement-activating surface, named the membra-
ne attack complex (MAC) (Fig. 1). 
Of the three initiating pathways the classical pathway (CP) is activated via binding of
its recognition molecule C1q to immunoglobulins i.e., IgG and IgM, acute phase pro-
teins, charged molecules, and apoptotic or necrotic cell debris. A conformational
change of the C1q molecule, when bound to its substrate, results in activation of the
serine proteases C1r and C1s, which are associated with the collagen-like tail of the
C1q molecule. C1s activate C4 and C2 leading to the formation of the C4b2a complex.
This complex or convertase leads to activation of the central complement component
C3. 
12
Chapter 1
13
Chapter 1
Figure 1. The three activation pathways of the complement system
(MAC= membrane attack complex)
The alternative pathway (AP) is activated by C3(H2O) which is continuously formed
by hydrolysis of C3. Activated C3 binds factor B and a C3 convertase, C3(H20)Bb, is
formed after cleavage and activation of factor B by factor D. This convertase is stabili-
zed by properdin and can subsequently activate C3. Activated C3 can bind factor B
and subsequent activation of factor B leads to formation of a more active C3 converta-
se, C3bBb. Activation of the alternative pathway is controlled by regulatory proteins
such as factor H and I.
Activation of the lectin pathway occurs in response to recognition of mannose-binding
lectin (MBL) and ficolins (L-ficolin and H-ficolin) of various carbohydrate ligands.
Complement activation and formation of the lectin pathway C3 convertase via MBL
and ficolins resemble the classical pathway, but MASP-2 appears to be responsible for
mediating the activation as a substitute for C1s. After activation of C2 and C4, the same
complement components as in the classical pathway cascade, the C3 convertase of the
lectin pathway, C4b2a, is formed.
The terminal pathway is similar for all three initiating pathways. Incorporation of a
C3b molecule in the C3 convertases leads to the formation of a C5 convertase. C5 is
C1q
MBL
Ficolins C3H2O
C4b2a C3bBb
C5b-9 (MAC)
Immune complexes
IgG IgM
Carbohydrates
IgA
Bacterial surfaces
LPS IgA
C3
Classical Pathway Alternative PathwayLectin Pathway
C2
C4
B
D
Properdin
C5
C6
C7
C8
C9
Terminal sequence
C3b
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activated and subsequent binding of C6, C7, C8, and C9 results in the formation of the
membrane attack complex C5b-9.
During the activation of complement, cleavage fragments of complement components
are generated which are chemotactic factors such as C5a.  Furthermore, C4b and C3b
can opsonize particles by binding to the surface leading to recognition of these parti-
cles by phagocytes. 
The major source of most circulating complement components is the liver. In contrast
to the components generated in the liver, C1q production is mainly extra-hepatic by
bone marrow-derived cells like macrophages and dendritic cells 41. However, many
other organs are capable of synthesizing complement components. There is increasing
evidence that this locally generated complement is biologically active and exerts
powerful effects within the local environment. For instance, it has been shown that
local production complement components is involved in immune mediated damage
and allograft rejection 42.
Soon after birth the serum complement levels reach adult levels under normal physi-
ological circumstances. Much less is known about differences in complement activity
in adults. Increase in classical pathway activity during age has been described with
increasing levels of C1q, C4, C3 and C9 43. For the alternative pathway reduced levels
of factor B with increasing age has been reported 43. Recently Ip et al.44 reported a ten-
dency to lower MBL concentrations in the elderly.  Also differences between comple-
ment levels and gender have been reported 45;46. The clinical relevance of the difference
in complement level between genders and during ageing remains to be established. 
Mannose binding lectin, one of the recognition proteins of the lectin
pathway of complement activation
Mannose-binding lectin
Mannose-binding lectin is one of the members of the human plasma lectins. Other
members are the pulmonary surfactant proteins SP-A and SP-D 47. These proteins,
also termed "collectins", belong to the C-type or CA2+ -dependent lectin superfamily 48.
Characteristic features of the collectins is that they contain a collagenous region and a
lectin domain (carbohydrate recognition domain, CRD) through which they can bind
various saccharides, a quality that enables the collectins to interact with different
microbial pathogens. MBL binding to sugar moieties involves hydrogen bonds of four
amino acid residues. The orientation of the hydroxyl groups determines the selectivi-
ty of MBL binding, N-acetyl glucosamine > L-fucose, mannose, N-acetyl mannosami-
ne > maltose > glucose >> galactose, N-acetyl galactosamine. The weak affinity of the
CRD for one monosaccharide makes multiple binding sites through clustering of CRD
and many repeating sugar groups on the microbial surface necessary. Because most
carbohydrate structures in animals are terminated by sugar moieties not recognised by
the collectins, such as galactose and sialic acid, MBL discriminates between self and
non-self. 
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Circulating MBL as well as other collectins comprise structural subunits each compo-
sed of three identical polypeptide chains of 32 kDa assembled to higher-order oligo-
meric structure containing two up to six of these trimeric subunits. Each chain consists
of a lectin domain, a hydrophobic neck region, a collagenous region and an N-termi-
nal region. Disulphide bridges and non-covalent bonds create stability between these
subunits. By electron microscopy the structure of MBL resembles a bouquet-like shape
similar to that of C1q (Fig. 2).
Figure 2. Schematic model of MBL.
MBL is mainly produced in the liver by hepatocytes and the rate of synthesis is to some
extent influenced by stress. Therefore MBL is reported as an acute phase protein 49. At
birth MBL plasma levels are about two thirds of adult levels. Within a few weeks after
delivery the adult plasma levels are reached 50. The plasma concentration of MBL
varies very much within the population from as low as a 10 ng/ml to 10 µg/ml. This
variation is largely genetically determined. The amount of MBL increases only up to
three-fold during an acute phase response. In contrast to one serum form of MBL in
man, in rodents two serum forms of MBL have been described 51. Both mouse MBL-A
and MBL-C are present in serum and are able to activate the MBL pathway of the com-
plement system 52.
The proteins of the collectin family are encoded by a cluster of genes on the long arm
of chromosome 10 53 apart from CL-P1 and CL-L1 which are located on chromosome 8
and 18, respectively. In man MBL is encoded by a single gene consisting of four exons
in contrast to rat and mice which have two functional MBL genes encoding the two
Crosslinking region
Collagen-like region
(similar to C1q)
Lectin domain /
carbohydrate recognition
domain
Neck region
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MBL serum forms 54. Exon 1 encodes the N terminal region, a cysteine rich-region and
part of the collagenous region. Exon 2 encodes the remainder of the collagenous
region. Exon 3 encodes the hydrophobic neck region and exon 4 the C-terminal carbo-
hydrate recognition domain. Upstream of the structural MBL gene the promoter
region of MBL is located 55. Four allelic forms of the MBL gene, i.e. the normal A allele
and three variant alleles, B, C and D have been reported. These SNP are found in the
collagen-like region and are considered to prevent the correct formation of a triple
helix. The first report on MBL deficiency due to a structural mutation in codon 54 of
exon 1 of the MBL gene (allel B) was in 1991 by Sumiya et al 56. This single nucleotide
polymorphism (SNP) at base 230 of exon 1 caused a change of codon 54 from GGC to
GAC. Substitution of an aspartic acid for a glycine in the translated protein affects the
secondary structural stability in the collagenous region of the molecule. This mutation
showed an autosomal dominant co-inheritance with low MBL levels. Also a SNP at
codon 57 (allele C), frequently found in sub-Saharan Africans, results in a replacement
of a glycine by a glutamic acid and disruption of the secondary structure 57. A third
mutation in exon one at codon 52 (allele D) of the MBL gene causes a replacement of a
cysteine for an arginine but with less effect on protein levels 58. SNPs have also been
described in the promoter region of the MBL gene influencing the gene expression and
thereby the MBL plasma concentration. This could explain the wide variation of serum
MBL concentrations found in A/A genotype individuals 55;59.
Function of mannose-binding lectin
Mannose-binding lectin as an element of the innate immune system plays an impor-
tant role in the first line of defence before the adaptive systems become active. Crucial
for innate as well as for adaptive defence is the central concept of distinguishing
between self and non-self, from potentially injurious and non-injurious microorga-
nisms. The innate immune system discriminates between self and non-self via patho-
gen-associated molecular patterns (PAMPs). These PAMPs are unique components of
the surface of infectious agents and are recognised by pattern-recognition receptors.
Mannose-binding lectin, as well as CRP and SAP are members of secreted pattern
recognition molecules 60. Other pattern recognition receptors are present as cell surfa-
ce receptors expressed on macrophages mediating phagocytosis of microorganisms.
For example, Macrophage mannose receptor (MMR) is a member of the C-type lectin
family and interacts with a variety of gram-positive and gram-negative bacteria and
fungal pathogens. 
A wide variety of bacteria, viruses and fungi are bound by MBL 61. Once MBL recogni-
zes a microbial surface complement is activated via MASP-2, which leads to opsoniza-
tion of microorganisms with C4b and C3b. Opsonized microorganisms can subse-
quently be cleared via complement receptors expressed on phagocytic cells 62. In addi-
tion, further activation of the complement system on the microbial surface may results
in the formation of the membrane attack complex and cell lysis. The clinical conse-
quence of MBL deficiency in relation to infectious diseases is discussed below.
The importance of innate immunity in host defence against invading microorganisms
is well established. In recent years it has become clear that the innate immune system
17
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also plays an important role in non-inflammatory handling of dying host cells. Binding
of MBL and other collectins to apoptotic material has been demonstrated 38.
Furthermore, enhanced uptake of apoptotic cells via MBL by macrophages is media-
ted by calreticulin and CD91. Also uptake of apoptotic cells by DC is facilitated by
MBL 63. The ligand for MBL on apoptotic material has not been identified yet. Recently,
DNA present on apoptotic material has been proposed as possible ligand for MBL on
apoptotic material 64. 
Mannose-binding lectin in disease
Infectious diseases
The importance of MBL for host defence in early childhood is well established and has
led to the suggestion that the role for MBL is particularly important after the decay of
passively acquired maternal antibodies and before the maturation of own antibodies
65. Furthermore, MBL has been hypothesised to act in the first line of defence at the time
of primary contact with invading microorganism and therefore called "ante-anti-
body"66. The importance of MBL in childhood is well illustrated in two large-scale stu-
dies on MBL deficiency and infections 67;68. In both studies an increased susceptibility
to infections was identified in heterozygous and homozygous MBL deficiency.
Preliminary results of a prospective study also confirmed the higher prevalence of
MBL mutant genotype in children with infectious diseases 69. More recently, associati-
on of MBL polymorphisms with sepsis and fatal outcome in patients with systemic
inflammatory response syndrome was reported 70. Also associations of MBL deficien-
cies with infections as complications in underlying diseases such as asthma, COPD,
cystic fibrosis and SLE have been demonstrated 71-74. On the other hand for some infec-
tious diseases one might benefit from an MBL deficiency as has been described for int-
racellular infections with M. tuberculosis and M. leprae 75;76.
Association of MBL deficiency with viral infections has also been investigated. MBL
deficiency predisposes to susceptibility to HIV infection 77-79. Reports on the progressi-
on of HIV in relation to MBL deficiency are conflicting 77;79;80. Also findings on the asso-
ciation of MBL deficiency with hepatitis C are controversial 81;82. MBL deficiency has
been shown to be associated with susceptibility and progression of hepatitis B 83;84.
Furthermore, MBL deficiency is found to be associated with the recurrence of candi-
diasis 85;86.
Non-infectious diseases
Rheumatoid arthritis
Inconsistent results have been reported on MBL insufficiency and predisposition to
rheumatoid arthritis 87-92. Some reports have suggested that MBL insufficiency might be
a progression factor in RA. However, other groups do not show an association
between MBL insufficiency and progression of disease 87. The mechanism by which
18
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MBL could influence inflammation in patients with RA has not been established.
Interaction of MBL with aggregated IgG-G0 has been demonstrated and might be
imported in RA 93. MBL has a binding affinity for IgG from patients with RA because
IgG from RA patients expose more N-acetylglucosamine, since the Fc-portion contains
less terminal galactose molecules (agalactosyl IgG or IgG-G0) 94. Binding of MBL to
IgG-G0 results in complement activation and therefore, might enhance clearance of
IgG-G0 immune complexes in patients with RA. On the other hand complement acti-
vation on IgG-G0 immune complexes present in the joints of RA patients might aggra-
vate joint destruction. Furthermore, enhanced risk for infections because of an MBL
insufficiency might also participate in the development of the disease in RA patients 90.
In mouse models it has been demonstrated using different complement knockout and
Fc-receptor knockout strains that activation of the alternative pathway and possibly
the MBL pathway of complement plays an important role in the pathogenesis of RA.
It has been hypothesised that the damage in RA is not caused by formation of the
membrane attack complex but by the chemotactic effect of C5a on neutrophils 95
IgA nephropathy
Primary IgA nephropathy is the most common form of glomerulonephritis worldwi-
de 96. Deposition of predominantly polymeric IgA of the IgA1-subclass and comple-
ment components are found in the glomerular mesangium 97. In rats complement acti-
vation by dimeric and polymeric IgA and subsequent glomerular damage has been
demonstrated 98. Abnormal glycosylation of IgA molecules has been proposed to play
a role in the pathological mechanism leading to renal deposition 98;99. The presence of
C3 in mesangium from patients with IgA nephropathy has been suggested to result
from alternative pathway activation because it is generally accepted that the classical
pathway of complement is not activated by IgA 100. However, in 30% of biopsies from
IgA nephropathy kidney also deposition of C4 is found98;101 and only in 6% deposition
of C1q. Therefore, complement activation via the MBL pathway has been suggested.
Co-deposition of IgA with MBL in kidney biopsies form IgA nephropathy patients has
been demonstrated 98;102. Furthermore, it has been shown that MBL binds to IgA via its
lectin domain resulting in activation of the complement system 103. Generation of the
C5b-9 complex in sublytic concentrations can activate the mesangium to produce
proinflammatory mediators as well as matrix proteins 98;104.
Systemic lupus erythematosus
From clinical studies in SLE patients it seems that MBL could play a role both in the
induction and in the effector-phase of the disease. MBL gene polymorphisms have
been shown to be associated with the onset and clinical presentation of SLE 72;105-108.
Although there are some conflicting results reported on this association 109, when inclu-
ding only studies with patients fulfilling at least four criteria for a proper diagnosis of
SLE, this association was recently confirmed in a meta-analysis 72. Disease severity and
complications are associated with MBL gene polymorphisms and suggest a possible
protective role for MBL in the effector-phase of the disease. Patients with an MBL gene
polymorphism tend to have a more severe disease expression and more frequent com-
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plications during their disease.  A possible pathogenic role for MBL in lupus nephritis
has also been suggested, showing the deposition of MBL and co-localisation of other
complement components in renal biopsies of lupus nephritis patients 110. 
Vascular disease
Increasing evidence supports the hypothesis that MBL activation on endothelial cells
might play an important role in the pathogenesis of different diseases. Complement
activation via MBL on (hypoxic) endothelial cells has been demonstrated in in vitro
studies. In vivo studies have shown that MBL-dependent complement activation after
ischaemia/reperfusion injury can cause tissue damage. Furthermore, inhibition of
mannose binding lectin pathway has been shown to reduce post-ischaemic myocardial
reperfusion injury in rats 111. A potential aggravating effect of the MBL pathway of com-
plement activation in humans at the level of endothelial cells subjected to oxidative
stress has been hypothesised. Supporting this theory are results on MBL-mediated
inflammatory response found after surgery for thoracoabdominal aortic aneurysm 112.
Furthermore, an association between mannose-binding lectin and vascular complica-
tions in type 1 diabetes has been demonstrated 113;114. In contrast, other studies have
demonstrated that diminished levels of MBL are predictive for coronary artery disea-
se 115. 
The function of MBL in diseases, as described above, appears to be on the one hand
protective while on the other had harmful. In infectious diseases MBL is most often
supportive in the defence against invading microorganisms, although some intracellu-
lar pathogens profit from the presence of MBL. For many inflammatory diseases MBL
protects against development or progression of the disease. However, for some disea-
ses activation of the complement system via MBL can induce an inflammatory respon-
se on tissue level. 
Complement deficiencies and disease
Complement deficiencies can be divided in primary or genetic complement deficien-
cies and secondary deficiencies due to complement consumption.  For most comple-
ment components genetic deficiencies are described 116. SLE and SLE-like disease are
associated with deficiencies of early complement components of the classical pathway,
whereas bacterial infections are associated with C3 deficiencies and deficiencies of
components of the alternative pathway and the terminal pathway. 
Complement activation is a response of the innate immune system on invading
microorganisms, circulating immune complexes and apoptotic material. However,
inappropriate activation of complement has been implicated in a number of diseases.
In some diseases autoantibodies against complement components interfere with com-
plement function and cause secondary complement deficiencies. In patients with
recurrent infections or systemic diseases where a complement deficiency is suspected,
serum can be screened for deficiencies by functional complement assays.  
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Assessment of the functional activity of the complement pathways
To assess the functional activity of the classical and the alternative pathway of comple-
ment activation, haemolytic assays are available. For assessment of classical pathway
(CH50) complement activation, sheep red blood cells (SRBC) are sensitised using rab-
bit anti-SRBC antibodies. For analysis of alternative pathway activity (AP50) rabbit
erythrocytes are used. Serum from patients is added to these erythrocytes and the
amount of erythrocyte lysis is used as a marker for complement activity of the classi-
cal and alternative pathway. Deficiency of complement components, decreased con-
centration or function of any component between the initiating component of the
pathway and the terminal complex, results in a decreased functional activity. 
Different assays have been developed to assess the functional activity of the lectin
pathway of complement. Some of the assays measure directly the functional activity of
the MBL/MASP complex by assessing the binding of this complex to a solid-phase
ligand and determining the activation of C4 117. To circumvent in these assays classical
pathway activation via C1q binding to anti-mannan antibodies, sera are incubation in
high sodium chloride buffers. At this tonicity, however, activation of C4 is also inhibi-
ted and therefore the activity of the MBL complex is assessed in a second step with
exogenously added purified C4. These assays do not assess the functional activity of
the whole MBL pathway up to the final common pathway of complement activation.
Measurement of full-length complement pathway activation leading to formation of
the membrane attack complex is performed for the classical and alternative pathway
by assessing the lysis of sensitised erythrocytes. Similar assays are developed for the
MBL pathway using mannan coated erythrocytes or by indirect lysis of erythrocytes
but these are only useful for experimental purposes 118;119.
Other assays are developed to assess the functional activity of the lectin pathway up
to the formation of C5b-9 with autologous complement components 120;121. Activation of
the classical pathway of complement is prevented by addition of an inhibitory anti-
body to C1q. Recently an ELISA-based assay has been developed to assess the functio-
nal activity of the three pathways of complement activation in one assay. 
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Scope of the thesis
The scope of the first part of the present study is to assess the role of the MBL pathway
as a two edged sword, in the pathogenesis of SLE. In the second part a new method to
assess MBL pathway activity was evaluated for clinical practise. 
The role for complement components from the classical and alternative pathway of the
complement system in SLE has been demonstrated in clinical and experimental stu-
dies in mice and man. A role for MBL in the pathogenesis of SLE in man has been
reported. The involvement of the MBL pathway of complement as a potential aggra-
vating factor in a murine model for lupus nephritis has been investigated in the pre-
sent study (Chapter 2).
Polyclonal B-cell hyper-reactivity resulting in the production of a wide variety of auto-
antibodies, of which many are directed against antigens present on apoptotic materi-
al, is a characteristic finding in patients with SLE. Therefore the prevalence of antibo-
dies against two complement proteins present on apoptotic material, MBL and C1q,
was studied in patients with SLE during active and inactive phases of disease. The cli-
nical consequence of the presence of anti-MBL and anti-C1q antibodies was investiga-
ted (Chapter 3). 
It has been demonstrated that polymorphisms of the MBL gene are associated with the
development of SLE. Furthermore, impaired complement-mediated clearance of apop-
totic material has been suggested to play a role in the pathogenesis of SLE. A possible
mechanism by which MBL might play a role in the development of SLE was examined.
Therefore, the production of autoantibodies against epitopes present on apoptotic
material in patients with an MBL polymorphism has been investigated. Furthermore,
MBL concentration, MBL-MASP complex activity and MBL pathway activity was stu-
died in patients with SLE in association with the presence of autoantibodies and disea-
se activity (Chapter 4). 
To assess the functional activity of the classical and alternative pathway haemolytic
assays are used. Until recently no such assay was available to assess the functional acti-
vity of the MBL pathway. In view of the clinical relevance of MBL deficiencies such an
assay would be very valuable. Therefore, a new assay has been developed to enable
the assessment of the functional activity of the whole MBL pathway and to determine
the classical and the alternative pathway functional activity in a simple uniform
design. Assessment of genetic complement deficiencies and secondary complement
deficiencies leading to a dysfunction of complement activation has been studied in a
standardised way (Chapter 5). 
This novel assay was used to assess to functional activity of the three pathways of com-
plement activation in healthy individuals in relation to age and gender (Chapter 6).
Finally, a discussion and summary of the results of the present thesis are given.
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Abstract
In Systemic Lupus Erythematosus (SLE), hypocomplementaemia and complement
deposition have been described both in man and in experimental models. A major
involvement of the classical pathway of complement activation has been demonstra-
ted in this disease, however relatively little is known about the involvement of the lec-
tin pathway. Therefore in the present study we have analyzed the activity of all three
pathways of complement activation in murine models of SLE.  In the mouse, MBL is
expressed in two forms, namely MBL-A and MBL-C. In the present study young and
old MRL-lpr and control MRL +/+ mice were compared for the levels of complement
activity with specific attention for the lectin pathway. It was found that upon aging of
both MRL-lpr and MRL+/+ mice, a marked decrease in the activity of the classical
pathway (CP) occurs. Levels of alternative pathway (AP) and lectin pathway (LP) acti-
vity remain unchanged. Key-molecules of these pathways, C1q, C3, MBL-A and MBL-
C were analyzed and were all found to be decreased in aged mice of both strains. The
levels of MBL-A and MBL-C showed a high degree of correlation and decreased equal-
ly. In aged MRL-lpr mice in which autoimmunity is most pronounced, we observed
high autoantibody titers and strong deposition of glomerular immune complexes in
association with deposition of C1q, C3, MBL-A and MBL-C. 
In conclusion, these data suggest that in addition to the classical pathway and the
alternative pathway also the lectin pathway of complement activation is involved in
murine lupus nephritis. 
Introduction
The lectin pathway (LP) of complement activation is involved in the innate defense
against pathogens (Petersen et al. 2001). However, the LP may also contribute to organ
damage (Ohsawa et al. 2001). The LP of complement activation is initiated by the bin-
ding of its recognition molecule Mannose Binding Lectin (MBL) to one of its natural
carbohydrate ligands (Petersen et al. 2001) as can be found on e.g. the surface of
microorganisms, IgA (Roos et al. 2001a) or altered-self molecules (Nauta et al. 2003).
Binding of MBL leads to the activation of MBL-associated serine proteases (MASP's).
Activated MASP-2 cleaves C4 and C2 in a similar way as C1s do for the Classical
Pathway (CP) leading to the formation of C4b2a, cleavage of C3, and complement acti-
vation up to the formation of the membrane attack complex (Petersen et al. 2001). MBL
may also directly opsonize microorganisms for phagocytosis by interaction with sever-
al cellular receptors (Kuhlman et al. 1989).
MBL deficiency or low levels of MBL in serum are frequently observed in the general
population due to single nucleotide polymorphisms in the structural region or the pro-
motor of the MBL gene (Garred et al. 2003). Low serum levels of MBL and increased
frequencies of MBL variant alleles have been described associated with a number of
diseases e.g. recurrent infections (Garred et al. 2002;Mullighan et al. 2002;Peterslund et
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al. 2001), recurrent abortion (Baxter et al. 2001) and SLE (Garred et al.
2001;Christiansen et al. 1999;Kilpatrick et al. 1999). This indicates that the LP is invol-
ved in protection against a great number of pathological conditions (Garred et al.
2003). In addition, MBL deposition and LP activation have been observed in several
renal diseases (Lhotta et al. 1999) such as IgA nephropathy (Endo et al. 1998) and lupus
nephritis (Lhotta et al. 1999) as well as in ischaemia reperfusion injury (IRI) (Collard et
al. 2000). On the other hand a protective role for MBL deficiency in relation to perito-
nitis (Takahashi et al. 2002) and inflammatory bowel disease (IBD) (Rector et al. 2001)
has been described. 
For humans, only one form of MBL has been described whereas for mice and
several other species two forms of MBL have been identified (Hansen and Holmskov
1998). Initially MBL-A has been considered the serum form in rodents and MBL-C a
liver form (Oka et al. 1988). However, recently both murine MBL-A and MBL-C have
been purified and characterized from serum (Hansen et al. 2000;Liu et al. 2001). In
order to be fully able to activate the complement system MBL needs to be in a proper
oligomeric structure. Both mouse MBL-A and MBL-C have now been reported to be
present in serum in high molecular weight forms, thus both allowing complement acti-
vation (Hansen et al. 2000). 
MRL-lpr mice provide a well-accepted model of murine SLE (Andrews et al. 1978).
These mice have a combination of an autoimmune-prone MRL background combined
with a mutation in the apoptosis-promoting Fas gene (lpr) (Watanabe-Fukunaga et al.
1992). MRL-lpr mice have a more severe and accelerated autoimmune disease compa-
red to MRL+/+ mice. Therefore comparing MRL-lpr and MRL +/+ mice of the same age
provides an insight in slow development of SLE in MRL +/+ mice and a more rapid
development of SLE in MRL-lpr mice. 
In the present study we have investigated the contribution of complement with speci-
fic attention for the LP of complement activation in murine lupus nephritis. MBL-A
and MBL-C concentrations in serum and depositions in the kidney were assessed in
MRL-lpr and MRL +/+ mice at 6 weeks of age and 4 months of age. As markers of auto-
immunity we have measured anti-Histone and anti-C1q autoantibodies (Trinder et al.
1995;Trouw L.A. et al. 2004b;Trouw L.A. et al. 2004a).
We observed that complement activity of the CP is decreased in old MRL-lpr mice
compared to young mice. However, AP and LP activity remained unchanged. Serum
levels of MBL-A and MBL-C were decreased in old MRL-lpr mice, as were C1q and C3.
Concomitant with the decrease in serum levels, C1q, C3 and MBL-A and MBL-C depo-
sited in the kidney, indicating that in addition to CP and AP also the LP is involved in
murine lupus-nephritis.
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Methods
Animals and experimental protocol
MRL/MpJ lpr mice (MRL-lpr) and MRL/MpJ +/+ mice (MRL +/+), female, 4 weeks of
age were obtained from the Jackson Laboratories (Bar Harbor, ME). All animals had
free access to water and standard chow. Animal care and experimentation were perfor-
med in accordance with the National Institutes of Health Guidelines for the care and
use of laboratory animals. Mice were divided in 2 groups of 12 MRL-lpr and 12 MRL
+/+ mice. We sacrificed one group of 7 MRL-lpr and 6 MRL +/+ mice at 6 weeks of age
the other two groups of 6 MRL-lpr and 7 MRL +/+ mice at 4 months of age. Prior to
sacrifice urine was collected in metabolic cages for 18 hours. At the appropriate time,
mice were anesthetized with urethane (Sigma-Aldrich, Zwijndrecht, The Netherlands)
and sacrificed by heart puncture. Blood was collected and allowed to clot for 6 hours
on ice. Serum was collected and stored in aliquots at -80
o
C until use.
Complement activity of the CP, AP and LP
For the detection of CP activity Microlon F-shape plates (Greiner bio-one, Alphen aan
de Rijn, The Netherlands) were coated with human IgM (Roos et al. 2003) at 3 µg/ml
for 2 hours at 37
o
C in coating buffer (100 mM Na2CO3/NaHCO3, pH 9.6). After incuba-
tion, plates were washed three times with PBS containing 0.05% Tween 20 (PBS-T).
Residual binding sites were blocked by incubation with PBS containing 1 % BSA (PBS-
BSA), for 1 hour at 37 
o
C. Sera were incubated in serial dilutions starting from 1:40 in
BVB++ (VBS containing 0.5 mM MgCl, 2 mM CaCl2, 0.05% Tween-20 and 1 % BSA, pH
7.5), for 1 hour at 37 
o
C. After washing, bound C3 was detected using rabbit anti-mouse
C3 (generated in our laboratory) conjugated to digoxigenin (Dig) (Boehringer
Mannheim, Mannheim, Germany) followed by HRP-conjugated sheep Fab anti-Dig
Abs (Boehringer Mannheim) in PBS-T-BSA, for 1 hour at 37 
o
C. Enzyme activity of
HRP was developed using 2,2'-azino-bis(3-ethyl benzathioline-6-sulfonic acid) (Sigma-
Aldrich). The optical density (OD) at 415 nm was measured using a microplate bioki-
netics reader (EL312e; Biotek instruments, Winooski, VT). For all complement activity
ELISA's normal mouse serum (NMS) from 10 weeks old male Swiss mice (Harlan,
Horst, The Netherlands), arbitrarily set at 1,000 aU/ml was used to produce a calibra-
tion curve. All ELISA's were performed using this protocol unless stated otherwise.
For the detection of AP activity plates were coated with 5 µg/ml LPS from S. typhosa
(Sigma), washed and blocked using PBS-BSA. Serial dilutions of sera were incubated
starting from 1:10 in GVB/MgEGTA (VBS containing 10 mM EGTA, 5 mM MgCl2,
0.05% Tween-20, and 0.1% gelatin; pH 7.5) for 1 hour at 37 
o
C. After washing bound C3
was detected using rabbit anti-mouse C3 conjugated to DIG and anti-DIG HRP.
For LP activity plates were coated with Mannan at 100 µg/ml (Sigma, M7504) washed
and blocked using PBS-BSA. After washing serial dilutions of sera were incubated
starting from 1:100 diluted in BVB++ buffer for 1 hour at 37 
o
C. Bound C3 was detec-
ted using rabbit anti-mouse C3 conjugated to DIG and anti-DIG HRP. 
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Detection of autoantibodies in serum
Anti-C1q autoantibodies were detected as described [26]. Briefly, C1q binding peptide
2J (Roos et al. 2001b) was coated at 12.5 mM in coating buffer for 2 hours at 37oC. Plates
were washed and incubated with serum of Rag2-/- mice as a source of C1q at 1:20 dilu-
tion in PBS-T-BSA for 1 hour at 37oC. Next, serial dilutions of serum samples were
incubated in PBS-T-BSA containing 0.5 M NaCl for 1 hour at 37oC. Bound mouse IgG
was detected using goat anti-mouse IgG-HRP (DAKO, Glostrup, Denmark). Anti-his-
tone autoantibodies were detected as described (Termaat et al. 1993). Data are expres-
sed relative to an anti-C1q and anti-Histone positive standard serum pool from old
MRL-lpr mice arbitrarily set at 1,000 aU/ml. 
Detection of levels of MBL-A, MBL-C, C1q and C3 in serum
Both MBL-A and MBL-C in serum were quantified using a commercial kit (HBT, Uden,
The Netherlands) as indicated by the manufacturer. Serum C1q was detected by ELISA
as described earlier (Trouw et al. 2003). Data are expressed relative to a standard
serum arbitrarily set at 1,000 U/ml. Serum C3 was detected by sandwich ELISA by coa-
ting goat anti-mouse C3 (Nordic, Tilburg, The Netherlands), and detection of bound
C3 by rabbit anti-mouse C3-Dig (generated in our laboratory) and anti-Dig-HRP
(Boehringer Mannheim). Data are expressed relative to a standard serum arbitrarily
set at 1,000 aU/ml. 
Renal function and pathology
To estimate renal function, serum samples were tested in a Blood Urea Nitrogen (BUN)
assay kit (Sigma). BUN levels were expressed in mg/dL. Albuminuria was measured
using an autoanalyser (Hitachi-911, Hitachi, Tokyo, Japan). Data are expressed as µg
albumin excretion per 24 hours.
Histological studies
For light microscopy, renal tissue was fixed in methyl Carnoy's solution, embedded in
paraffin and 3 µm sections were stained with hematoxylin-eosin (HE) or periodic acid-
Schiff (PAS). Evaluation of histo-pathologic changes was performed on coded sections
by a pathologist (IB) and expressed as an Activity Index (AI) and Chronicity Index (CI)
as described by Austin et al.. These indexes score several parameters of active renal
inflammation such as glomerular proliferation, leukocyte exudation,
karhyorrhexis/fibrinoid necrosis and hyaline deposits as well as chronic alternations
such as glomerular sclerosis, fibrous crescents, tubular atrophy and interstitial fibrosis
(Austin, et al. 1984).
For immunohistochemistry, acetone fixed, 3 µm, cryostat sections of snap frozen tissue
were stained with Oregon Green-conjugated goat anti-mouse IgG (Molecular probes,
Leiden, The Netherlands), or FITC-conjugated goat anti-mouse IgM (Nordic).  Mouse
C1q was detected using rabbit anti-mouse C1q (Trouw et al. 2003) and goat anti-rabbit
IgG FITC (Nordic). Mouse C3 was detected using goat anti-mouse C3 FITC (Nordic).
Mouse MBL-A and MBL-C were detected using rabbit anti-mouse MBL-A and MBL-C
antibodies that were generated and described previously (Wagner et al. 2003), follo-
wed by goat anti-rabbit FITC (Nordic).
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Statistics
Statistical analysis was performed using GraphPad Prism 3.03 software. Differences
between groups for various parameters were tested for significance using Mann
Whitney tests. Correlations between several parameters were analyzed using
Spearman rank correlation tests. P values were considered statistically significant
when P < 0.05. 
Results
CP activity decreases with age in MRL-lpr mice but AP and LP activity remain
constant
We have analyzed serum samples of MRL +/+ and MRL-lpr mice of 6 weeks of age and
4 months of age and assessed the activity of the CP, AP and LP in serum by ELISA. CP
activity is decreased by 63% in old MRL-lpr mice compared to young MRL-lpr mice (p
= 0.0221) (Figure 1A). There was no significant difference in CP activity between MRL
+/+ mice of both ages. For AP activity there was a trend towards lower AP activity in
aged mice of both strains. We observed an average reduction in AP activity of 52% and
63% for MRL+/+ and MRL-lpr mice respectively, but due to the variance this was not
statistically significant. (Figure 1B). There was no difference in LP activity between
young versus old MRL-lpr or MRL +/+ mice (Figure 1C). In order to rule out that pre-
formed antibodies against mannan may activate the CP in our LP assay we have per-
formed three experiments. Firstly, we have analyzed the deposition of mouse immu-
noglobulins from sera of young and old C57BL/6 mice as well as MRL+/+ and MRL-lpr
mice and repeatedly found no significant binding. Secondly, we performed the assays
for LP and CP activity in the presence of D-Mannose, which resulted in inhibition of
LP only, indicating that the assay for LP activity is MBL dependent. Thirdly, we have
compared NMS with C1q-/- serum and found no difference in LP activity. Together,
these data strongly suggest that the CP does not contribute to LP activity in the cur-
rent assay (data not shown). 
C1q, C3, MBL-A and MBL-C all are decreased in serum of old mice
Using sandwich ELISA's we quantified the concentration of C1q, C3, MBL-A and
MBL-C in serum of young and old mice of both strains. Serum C1q concentrations
were decreased by 66% in old MRL-lpr mice (p = 0.002) compared to young MRL-lpr
mice as well as to old MRL+/+ mice (p = 0.05). In fact two mice had nearly undetecta-
ble levels of serum C1q (Figure 2A). C1q levels did not change in MRL +/+ mice.
Interestingly the young MRL-lpr mice had a higher C1q concentration than either
young or old MRL+/+ mice. C3 levels were decreased by 31% in old MRL-lpr mice (p
= 0.041). C3 levels did not change significantly in MRL +/+ mice (Figure 2B). 
Both MBL-A and MBL-C serum levels were decreased in old MRL-lpr mice compared
to young MRL-lpr mice (Figure 2C,D) by 50% and 41% respectively (p = 0.026 and p =
0.0022). MBL-C was also decreased upon aging in MRL+/+ mice by 21% (p = 0.035)
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Figure 1 Activity of the CP, AP and LP of com-
plement activation as assessed by ELISA. (A)
Classical pathway activity (B) Alternative
pathway activity and (C) Lectin pathway activity
of young and old MRL-lpr and MRL +/+ mice.
Dots represent individual mice, lines represent the
median. C3 deposition induced by each pathway
was detected and related to a standard serum with
an activity of 1,000 aU/ml. 
whereas MBL-A was not decreased. Comparison of MBL-A and MBL-C levels in all
serum samples revealed a strong correlation between the titers of these two proteins (r
= 0.67, p = 0.00062) (Figure 2E).
Autoantibodies in relation to complement activity
We have analyzed both anti-histone and anti-C1q autoantibodies as parameters of
autoimmunity. Anti-histone autoantibodies were absent in young MRL +/+ mice and
are significantly increased upon aging. In some young MRL-lpr mice anti-histone anti-
bodies could be detected and a pronounced increase in anti-histone titer was observed
in old mice (p = 0.0012)(Figure 3A). Anti-C1q autoantibodies were slightly positive in
young MRL+/+ mice and did not increase significantly upon aging. Young MRL-lpr
mice already had some anti-C1q reactivity which was strongly increased upon aging
(p = 0.0012) (Figure 3B). We have analyzed the relation between anti-histone and anti-
C1q titer with activity of the CP, AP or LP. For this analysis we have used the samples
of both strains of both ages. Anti-C1q titers and anti-Histone titers were correlated (p
= 0.001). Levels of anti-histone autoAb correlated to CP (p = 0.007) and AP (p = 0.008)
activity but not to LP activity (p= 0.749). Anti-C1q autoAb levels were correlated with
CP activity (p = 0.037) but not with AP or LP activity (p = 0.070 and p= 0.308).
Renal deposition of IgG, C1q, MBL-A, MBL-C and C3
Staining renal sections of MRL +/+ and MRL-lpr mice for mouse IgG as a measure of
immune complex deposition revealed background positivity of mouse IgG in glome-
ruli of young MRL +/+ mice and increased positivity of IgG in glomeruli of old MRL
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Figure 2 Serum levels of C1q, C3 and MBL-A and MBL-C in young and old MRL+/+ mice and MRL-
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+/+ mice and young MRL-lpr mice. Massive IgG deposition was observed in old MRL-
lpr mice. 
Staining these sections for the deposition of mouse C1q revealed a similar profile with
especially glomeruli of old MRL-lpr mice being brightly positive. Normal mouse kid-
neys (data not shown) and kidneys of young MRL +/+ and MRL-lpr mice were slightly
positive for MBL-A and negative for  MBL-C except for slight positivity in young MRL-
lpr mice. The positivity for MBL was mainly found in large vessels, peri-tubular capil-
laries and glomerular capillaries (Figure 4). Upon aging both MBL-A and MBL-C
deposited in glomeruli, now in a capillary and mesangial pattern (Figure 4). The inc-
reased deposition was more pronounced in MRL-lpr mice than in MRL +/+ mice. MBL-
A seems to be more abundantly present than MBL-C. Staining for C3 as a marker of
complement activation revealed a similar pattern as that for IgG, C1q and MBL-A and
MBL-C.
Renal function and albuminuria in relation to MBL concentrations
We have analyzed renal function using BUN, and observed mean BUN values in
MRL+/+ mice of 33 mg/dL which decreased slightly upon aging. Young MRL-lpr mice
had BUN values around 25 mg/dL and this value rose significantly to 37 mg/dL in old
MRL-lpr mice. These data indicate that renal function is affected but not completely
lost in our cohorts (Figure 5A). We have also analyzed albuminuria as a measure for
renal injury and observed no albuminuria in either young or old MRL+/+ mice (Figure
5B), while two old MRL-lpr mice clearly develop albuminuria (Figure 5B). MBL-A con-
centrations as analyzed for all mice together did not correlate with either BUN or albu-
min values, whereas for MBL-C there was a negative correlation with the BUN values
(p = 0.03).
Assessment of histological changes in renal sections revealed no chronic changes in
our cohorts. For the activity index (AI) mostly glomerular cell proliferation and leuko-
cyte influx were observed, but also occasional cellular crescents and hyaline deposits.
Both young and old MRL+/+ mice displayed only marginal signs of renal inflammati-
young old young old
0
100
200
300
400
p = 0.0023 p = 0.0012
A
n
ti
-h
is
to
n
e
a
U
/m
l
MRL +/+ MRL-lpr
A
Figure 3 Autoantibody titers in young and old MRL+/+ and MRL-lpr mice.
Anti-histone autoantibodies (A) and anti-C1q autoantibodies (B) as detected by ELISA. Dots
represent individual mice, lines represent the median. Autoantibody titers are expressed as aU
relative to a standard serum, which was arbitrarily set at 1,000 aU/ml.
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on. Young MRL-lpr mice displayed a slightly increased histopathological score when
compared to MRL+/+ mice and upon aging this index rises sharply in MRL-lpr mice (p
= 0.002) (Figure 5C). The AI was negatively correlated to both MBL-A and MBL-C (p =
0.04 and p = 0.02 respectively).
Discussion
The lectin pathway of complement activation has been extensively studied because of
the associations between functional deficiencies and several diseases (Baxter et al.
2001;Garred et al. 2002;Garred et al. 2003;Mullighan et al. 2002;Peterslund et al. 2001).
However, the contribution of the lectin pathway to organ damage has not been inves-
tigated in detail. In SLE and lupus nephritis complement activation is thought to play
a potential role in organ damage (Cameron 1999;Walport 2001a;Walport 2001b).
Several reports describe a relation between decreased levels of CP and AP components
and organ damage (Buyon et al. 1992;Gunnarsson et al. 2002;Siegert et al. 1991;Sturfelt
2002). No such data is available for LP components. Therefore we have analyzed whe-
ther the lectin pathway of complement activation is involved in murine lupus nephri-
tis. 
To investigate the contribution of the lectin pathway to murine lupus-nephritis we
have used MRL-lpr and MRL +/+ mice. These mice develop a spontaneous autoimmu-
ne disease, which is accelerated in MRL-lpr mice by the silencing of the Fas gene.
Therefore MRL-lpr have a fast and aggressive autoimmune disease and MRL+/+ mice
have a milder autoimmune disease when compared at the same age. The role of com-
plement in murine lupus nephritis became questionable since some studies using C1q-
deficient (Mitchell et al. 2002) and C3-deficient (Sekine et al. 2001) MRL-lpr and
MRL+/+ mice suggested that complement activation is not essential in murine lupus
nephritis. However, recent experiments using Crry-Ig, a rodent complement inhibitor
at the level of C3, showed that inhibition of complement activation prevented renal
damage in MRL-lpr mice (Bao et al. 2002;Bao et al. 2003a;Bao et al. 2003b). These data
and data from factor B-deficient MRL-lpr mice (Watanabe et al. 2000) clearly indicate
that complement does play a role in this disease and that these mice provide a good
tool to study the contribution of the lectin pathway to murine lupus nephritis.
In the present study we observed a decrease in CP activity in MRL-lpr mice upon
aging. The AP and LP activity remained unchanged. The decrease in CP activity may
to some extent be explained by the decrease in key molecule for the CP C1q.
Interestingly the key-molecules of the AP, C3 and for the LP, MBL-A and MBL-C were
both reduced upon aging of MRL-lpr mice whereas AP and LP activity remained
unchanged. For the AP activity a trend of reduced AP activity was obvious however
due to variance it did not reach statistical significance, whereas the decrease in C3
levels was borderline significant, therefore we feel that this is not in disagreement with
each other. For the discrepancy observed for the LP, these data may suggest that other
molecules that are able to bind to mannan might support LP activity in these aging
mice. It has been reported that human L-ficolin and H-ficolin are able to activate the
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LP. However, this has not been reported for mouse molecules. Furthermore, human
ficolins do not bind to mannan and therefore their contribution to LP activity in MRL-
lpr mice is considered unlikely. 
In order to rule out that our detection system for LP activity may also allow comple-
ment activation via the CP, mediated by the binding of anti-mannan antibodies as has
been described previously for human serum (Roos et al. 2003), we have performed
several experiments. Firstly, we have analyzed the deposition of mouse immunoglobu-
lins from mouse sera of young and old non-autoimmune C57BL/6 mice as well as auto-
MRL +/+ MRL-lpr
MBL-A
MBL-C
IgG
C1q
C3
young oldold young
Figure 4 Immunofluorescence analysis of renal deposition of MBL-A, MBL-C, IgG, C1q and C3.
Renal sections of either young or old MRL+/+ or MRL-lpr mice were stained for the presen-
ce of mouse MBL-A, MBL-C, IgG, C1q or C3. Representative pictures are shown. Original 
magnification 400 x.
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immune prone MRL+/+ and MRL-lpr mice and we repeatedly found no significant bin-
ding of mouse immunoglobulins to these mannan coated plates. Secondly, we have
performed the assays for LP and CP activity in the presence of D-Mannose (a well
known ligand for MBL), resulting in inhibition of only LP assay indicating that com-
plement activation in the LP test is MBL dependent. Thirdly, we have compared NMS
with C1q-/- serum and found no difference in LP activity. Together, these data stron-
gly suggest that the CP does not contribute significantly to LP activity in our assay.
Deposition of immune complexes in glomeruli is thought to be an initiating event in
the pathogenesis of lupus-nephritis (Cameron 1999;Oates and Gilkeson 2002). We
observed IgG positivity paralleled by C1q positivity, indicating CP involvement. In
addition we observed C3 deposition which can be activated via all three pathways of
complement activation, and deposition of MBL-A and MBL-C, indicating that also the
LP is involved. In the present study we can not conclude on the relative contribution
of the three pathways of complement activation, but we do show that MBL-A and
MBL-C are decreased in serum and do deposit in the kidney during murine lupus-
nephritis. One report describes the deposition of MBL in several forms of glomerulo-
nephritis including lupus-nephritis (Lhotta et al. 1999). These authors state that MBL
is found on the same locations where IgG deposition and CP activation have taken
place and suggest that MBL may bind to agalactosyl oligosacharides of IgG that termi-
nate in N-acetylglucosamine. Also in this mouse model of lupus nephritis we observed
MBL deposition on the same locations as IgG and C1q. In line with our observation in
mice one report also describes decreased levels of MBL during lupus nephritis in
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humans (Lau et al. 1996). However others have reported the serum concentration of
MBL to be in the same range as the MBL concentration of healthy individuals (Lhotta
et al. 1999). Both disease activity and treatment may be different between these two
reports and may account for these differences.
Deficiencies of early components of the CP (C1q, C1r, C1s, C4) are strongly related to
an increased susceptibility to SLE (Botto et al. 1998;Mitchell et al. 2002;Walport 2001b).
MBL deficiency is also associated with an increased risk to develop SLE (Garred et al.
2001), although to a much lesser extent. Furthermore, MBL deficiency was shown to be
associated with a higher disease activity and an enhanced risk for infections in SLE
patients (Garred et al. 2001). In autoimmune diseases one can distinguish induction of
autoimmunity and organ damage as two separate events. Therefore if genetic analysis
indicates that a component is protective against autoimmunity, it may still very well
contribute to organ damage in WT individuals. Data from the present study as well as
previously reported findings in human lupus nephritis, suggest that MBL may also
contribute to organ damage in SLE and therefore could have a dual role in this disea-
se. In this respect, it has been reported that MBL deficiency contributes to an earlier
and more severe development of rheumatoid arthritis whereas, MBL wildtype alleles
were also associated with additional joint inflammation (Garred et al. 2000).
In conclusion, the present study provides evidence that the lectin pathway of comple-
ment activation is activated in murine lupus nephritis based on the observation that
the serum concentrations of both MBL-A and MBL-C are decreased as lupus nephritis
develops and that these components deposit in the kidney in a similar pattern as C3,
possibly contributing to renal damage.
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Summary
In systemic lupus erythematosus (SLE), autoantibodies directed against complement
components of the classical pathway, especially against C1q, are associated with seve-
re disease and are of prognostic value for flares of lupus nephritis.  Mannose-binding
lectin (MBL), the recognition unit of the MBL pathway of complement activation, has
structural similarities with C1q. Deficiencies of MBL have been shown to predispose
to the development of SLE and to influence the course of the disease. We hypothesised
that the presence of autoantibodies to MBL analogous to autoantibodies to C1q in
patients with SLE may contribute to disease development. 
The occurrence of anti-MBL autoantibodies was assessed by ELISA in 68 serum sam-
ples from 20 patients with SLE and in serum from 70 healthy controls. Levels of anti-
bodies directed against MBL were significantly higher in patients with SLE compared
to healthy subjects. No significant difference was found between patients with active
disease compared to inactive disease. While the occurrence of anti-C1q autoantibodies
was associated with renal involvement, no such relation was found for anti-MBL auto-
antibodies. A significant correlation was found between anti-MBL and anti-C1q anti-
body levels. The level of anti-MBL antibodies was negatively correlated with MBL-
complex activity of circulating MBL. Anti-MBL autoantibodies were of IgG isotype
and the binding site of IgG anti-MBL was located in the F(ab')2 portion.  
We conclude that anti-MBL antibodies are present in sera from patients with SLE and
influence the functional activity of MBL. 
Introduction
The innate immune system plays a crucial role in the pathogenesis of systemic lupus
erythematosus [1,2]. In the pathogenesis of SLE the complement system has a dual
role. On the one hand activation of complement may cause tissue injury, on the other
hand, genetic deficiencies of complement components, especially of the early compo-
nents of the classical pathway, are strongly associated with the occurrence of SLE [3].
Furthermore, the presence of antibodies to C1q is associated with hypocomplementa-
emia and nephritis in patients with SLE [4-7]. Recent studies indicate a possible role
for the lectin pathway of complement activation in the pathogenesis of SLE [8,9]. 
Mannose-binding lectin (MBL), structurally homologous to C1q, activates the lectin
pathway of complement. Like C1q, MBL consists of trimeric subunits with a collagen-
like tail. These subunits assemble to higher-order structures consisting of up to six tri-
mers [10]. Binding of the carbohydrate-recognition domain of MBL to different carbo-
hydrates, in a calcium-dependent manner, activates the MBL-associated serine protea-
ses MASP-1, MASP-2 and MASP-3 that are strongly related to the serine proteases of
the classical pathway, C1r and C1s. Evidence has been provided that activation of
MASP-2 is responsible for the activation of the complement cascade [11].
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MBL deficiency or low serum MBL levels are frequently found in the general popula-
tion due to point mutations in the structural portion or promoter region of the MBL
gene [9-12]. The three known mutations in the structural domain of the MBL gene are
located in codon 52 [13], 54 [14] and 57 [15] of exon 1, whereas mutations at position -
550 (H/L alleles), -221 (X/Y alleles) and  +4 (P/Q alleles) upstream of the MBL gene are
located in non-coding regions [16,17]. Circulating concentrations of MBL have been
shown to be associated with recurrent bacterial and fungal infections in both children
and adults [18-21]. Variant alleles, leading to reduced serum concentrations of MBL,
may be associated with the predisposition for SLE [8,22-25]. Association of a promotor
polymorphism with the development of SLE has been reported [26-28]. Furthermore,
complications caused by bacterial infections in patients with SLE occur more frequent-
ly if these individuals carry mutations in the MBL gene [24,29].
Autoantibodies to C1q are found in 30-45% of patients with SLE [4-7,24]. The presen-
ce of anti-C1q autoantibodies is associated with hypocomplementaemia and glomeru-
lonephritis. In the presence of anti-C1q antibodies the C1q levels are reduced [6].
Stabilisation of deposited C1q in the kidney, by these antibodies, has been suggested
to cause ongoing complement activation and thereby damage to the kidney [30].
Increase of anti-C1q levels in serum of patients with SLE is strongly associated with
flares of lupus nephritis [5-7,31]
Low MBL concentrations may result from gene polymorphisms, consumption of MBL
during disease activity or possibly because of autoantibodies directed against MBL.
Because of the structural similarities between C1q and MBL, and the role of MBL in
patients with SLE, we investigated if, analogous to the presence of anti-C1q autoanti-
bodies,  autoantibodies to MBL occur. 
Patients and Methods
Patients
All 20 patients with SLE (5 males and 15 female; mean age 33  years) visited the out-
patient clinic of the department of Nephrology. The patients fulfilled the American
Rheumatological Association (ARA) criteria for SLE. The clinical data were recorded
from the patient files. From each patient at least two serum samples were obtained
over time, the maximum number of serum samples/patient was seven. The total num-
ber of serum samples from the 20 patients was 68. Samples were taken (after obtaining
informed consent from the patient) during inactive and active phases of disease. The
autoantibody titres were measured in different serum samples from each patient
during active and inactive disease. Active disease was considered to be present when
patients had disease activity ( as defined by clinical criteria) or when laboratory results
indicated active nephritis, i.e. proteinuria > 0.5 g/24 h and  erythrocytes ( or red cell
casts) on urinalysis. The serum aliquots were stored at -20
o
C until required for further
use. From 70 healthy individuals, working in our hospital, serum samples were obtai-
ned and used as controls.
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Purification of MBL and measurement of MBL serum concentrations
Purification of MBL and the assessment of MBL concentrations was performed exact-
ly as described previously [32]. 
Detection of immunoglobulin G (IgG) binding to MBL
For detection of IgG antibodies to MBL, Nunc Maxisorb plates (Roshilde, Denmark)
were first coated, for 2 h at 37oC , with  0.5 µg/ml MBL in coating buffer (100 mM
Na2CO3/NaHCO3, pH 9.6). After incubation, the plates were washed three times with
phosphate-buffered saline (PBS) containing 0.05% Tween-20 (PBS/Tw). Unoccupied
binding sites were blocked by incubation for 1 h at 37
o
C with 0.01% gelatin in PBS.
Serum samples diluted in PBS/Tw, containing 1% bovine serum albumin
(PBS/Tw/BSA) and 10 mM EDTA were incubated on the plate for 1 hr at 37oC. After
incubation, bound IgG was detected using digoxigenin (Dig) (Boehringer Mannheim,
Mannheim, Germany)-conjugated monoclonal mouse anti-human IgG (HB43, mAb
anti-IgG, hybridoma obtained from the American Type Culture Collection (ATCC)),
diluted in PBS/Tw/BSA. Subsequently, HRP-conjugated Fab rabbit anti-Dig Abs
(Boehringer Mannheim) were added and enzymatic activity of HRP was assessed
using 2,2'-azino-bis(3-ethyl benzathioline-6-sulfonic acid) (Sigma, St. Louis, MO). The
optical density (OD) at 415 nm was measured using a microplate biokinetics reader
(EL312e; Biotek instruments, Winooski, VT). The concentration of IgG reactive with
MBL is expressed in units/ml of serum (U/ml), related to a standard serum. Values
below the detection limit of the assay (OD value < 1.5-fold the OD value of back-
ground) were given an arbitrary value of 40 U/ml Pooled sera from patients with SLE
were used as standard serum. The concentration of IgG reactive with MBL in the stan-
dard serum was arbitrarily set at 1000 U/ml. 
Detection of circulating complexes of MBL and IgG binding to MBL.
Microtiterplates were coated with monoclonal mouse anti-human MBL (3E7, kindly
provided by Dr. T Fujita, Fukushima, Japan) or an isotype-matched control mouse
monoclonal antibody (IgG1 anti-rat kappa chain). After a blocking step, serum sam-
ples were incubated (diluted 1:10) and IgG binding was detected as described above.
Detection of anti-C1q Ab
Anti-C1q autoantibodies were assessed as described previously [6,33]. Purified C1q (2
µg/ml)  was coated on  96-well Nunc Maxisorb plates in coating buffer, in a final volu-
me of 100 µL, for 2 h at 37oC. Plates were washed with PBS/Tw for three times after
each incubation period. Serum samples were diluted in PBS/0.05% Tween/1% FCS/1M
NaCl for 1 h at 37 
o
C. IgG antibodies were detected using digoxigenin (Dig)- conjuga-
ted monoclonal mouse anti-human IgG (HB43), as described above. This assay is used
as a routine diagnostic assay in our laboratory for detection of anti-C1q. Values > 90
U/ml, compared to a standard serum, are considered as high.
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Functional activity of the MBL complex activity
MBL complex activity was assessed using the method described by Petersen et al. [34]
with slight modifications. In brief, mannan-coated plates were incubated with serum,
diluted in GVB++ ((VBS (1.8 mM Na-5,5-diethylbarbital, 0.2 mM 5,5-diethylbarbituric
acid, 145 mM NaCl) containing 0.5 mM MgCl2, 2 mM CaCl2, 0.05 % Tween-20, and 0.1
% gelatin; pH 7.5)) containing 1 M NaCl, for 16 h at 4 °C. Plates were washed with
PBS/Tween containing 5 mM CaCl2, followed by incubation with purified C4 [32] (1
µg/ml), diluted in VBS containing 1 mM MgCl2, 2 mM CaCl2, 0.05 % Tween-20, and 1
% BSA, pH 7.5, for 1 h at 37°C. Activation of C4 was assessed using mAb C4-4a (anti-
human C4d, from Dr. C.E. Hack) conjugated to Dig. Functional activity was expressed
in arbitrary units/ml (aU/ml), based on serial dilutions of a human pool serum that was
used as a standard on each plate. Activity of this standard was set at 1000 U/ml.
Isolation and characterisation of MBL-binding immunoglobulin
To determine the type and size of the immunoglobulin binding to MBL, 3 ml of serum
from a patient with SLE was applied to a Superdex HR 200 column (Pharmacia,
Uppsala, Sweden) equilibrated with PBS, and fractions of 2.0 ml were collected. Total
protein concentration in the fractions was determined in a bicinchonini acid (BCA)
protein assay (Pierce, OMNILAB, Breda, The Netherlands). Size marker proteins IgM,
IgA and IgG, and IgG anti MBL Ab were assessed by ELISA of the fractions.   
Isolation of F(ab')2 fragments.
IgG was purified from 2 ml serum obtained from a pool of five sera from patients with
known reactivity against MBL as well as from serum from a healthy volunteer. Pepsin
digestion was performed using pepsin at a 1:10 (w/w) pepsin/protein ratio for 18 h at
37
o
C in Whalpole buffer. The reaction was stopped by addition of 1 M Tris base, 250
µl/ml digest. The mixture was applied on a G150 Sepharose column (Pharmacia) to
separate the F(ab')2 fragments from the undigested IgG. Binding of F(ab')2 fragments
to MBL was assessed using a rabbit anti-human light-chain (kappa and lambda) anti-
body.
Statistics
The Mann-Whitney U test, the Kendall tau-b non-parametric correlation coefficient
and the Fisher exact test were used. P-values < 0.05 were considered statistically signi-
ficant.
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Results
Detection of anti-MBL autoantibodies in patients with SLE
First, the presence of anti-MBL antibodies was investigated in sera from patients with
SLE. A pool of sera with demonstrable activity was made and further examined. Using
this serum pool, a dose-dependent binding of IgG to solid-phase MBL was demonstra-
ted, while a serum from a healthy control did not show significant reactivity (Fig. 1A).
This assay was performed in the presence of EDTA to prevent MBL binding via its C-
type lectin domains. This serum pool was used as a standard serum for further expe-
riments. As a control, ELISA wells were coated with gelatin alone; no detectable IgG
binding was observed (Fig. 1B). Binding of IgG to MBL could not be inhibited by addi-
tion of an excess of purified MBL in the fluid phase, suggesting that the antibody is pri-
marily binding to solid-phase MBL (results not shown). 
Subsequently, IgG anti-MBL autoantibodies were identified in 68 sera from 20 patients
with SLE and 70 samples from healthy controls. The frequency of the clinical variables
of disease activity that were observed at any period during disease activity are presen-
ted in Table 1. 
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Figure 1. Binding of IgG to immobilised MBL. 
Microtiterplates were coated with MBL (A) or gelatin (B). Pooled serum from patients with 
SLE (standard serum,) or a healthy control serum were added in serial dilutions in the pre-
sence of EDTA (10 mM). Binding of IgG was analysed. Results represent the mean value ± 
standard deviation (s.d.).
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The results of anti-MBL measurements were expressed in units relative to the standard
serum. Statistical analysis was performed on the mean level of anti-MBL IgG of the dif-
ferent serum samples from one patient. Levels of anti-MBL autoantibodies were signi-
ficantly higher in patients with SLE than in healthy controls (Fig. 2A). When the anti-
Table 1. Clinical presentation of disease activity in 20 patients with SLE
Clinical variable of Number of patients Occurrence of disease
Disease activity of patients parameters
(% of patients)
General 10
Fatigue 30
Fever 10
Raynaud's phenomenon 20
Skin 11
Erythema 35
Photosensitivity 30
Oral ulcers 25
Dscoid lesions 15
Vasculitis 20
Alopecia 25
Joints 13
Arthritis 50
Arthralgia 30
Tendinitis 5
Serosa 7
Pericarditis 25
Pleuritis 30
Peritonitis 10
Kidney 15
Proteinuria1 75
Haematuria2 75
Nervous system 4
Seizure 0
Cva 5
Lupus headache 5
Mononeuritis multiplex 5
Personality disorder 10
1> 0.5 g/ 24 h
2> 10 RBC / high power field
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MBL titers were compared between sera obtained during inactive and active phases of
disease, no significant difference was found (Fig. 2C). In the same samples, anti-C1q
levels were also determined (Fig. 2B). A significant difference in anti-C1q titre was
found between sera of patients with SLE as compared to controls.  As expected signi-
ficantly higher anti-C1q levels were found in SLE sera during active disease compared
with inactive disease (fig 2D).
Association of anti-MBL autoantibodies with disease activity and correlation with
the presence of anti-C1q
Anti-C1q antibody levels are elevated in patients with active SLE and predictive for
renal disease [4-7,31]. We investigated whether the presence of high anti-MBL levels
was associated with disease activity and predictive for renal involvement.
In the sera studied (n=68), we detected a significant association with active disease for
high levels of anti-C1q, but not for anti-MBL antibodies (Table 2A). Furthermore,
Figure 2 Anti-MBL and anti-C1q autoantibodies in different serum samples
(A) Anti-MBL reactivity was measured in 68 serum samples of 20 patients with SLE and in
70 samples from healthy controls. (C) Anti-MBL autoantibody levels of samples obtained 
during inactive and active phases of disease. (B) Anti-C1q levels in patients with SLE and 
healthy controls. (D) Anti-C1q autoantibody levels of samples obtained during inactive and 
active phases of disease. The median of each group is indicated by the solid line.  The dashed 
line indicates the detection limit. aU, arbitrary units.
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levels of anti-MBL antibodies in patients with  SLE with renal involvement were sta-
tistically not different from levels in patients without renal involvement. For anti-C1q,
as expected, antibody levels were significantly higher in patients with renal involve-
ment (Table 2B).
As anti-C1q antibodies are directed mostly against the collagenous tail of C1q [35], we
investigated whether there was any correlation with the occurrence of anti-MBL anti-
bodies.  The presence of anti-C1q was significantly associated with the presence of
anti-MBL antibodies (Table 3) and a statistically significant correlation was found
between the anti-MBL and anti-C1q levels (R =0.21, P=0.004) .
Number of sera with Number of sera with
high or low anti-C1q levels high or low anti-MBL levels
Disease activity >90 aU/ml <90 aU/ml >100 aU/ml <100aU/ml
Inactive 17 13 15 17 
Active 34 4 22 14 
Fisher exact test P=0.005 Fisher exact test P=0.3
The value for high levels of anti-MBL was set at a level at which te10% percent of the healthy control group were considered as
having high anti-MBL levels. Thereb, anti-MBL levels >100 aU/ml were defined as high.
Table 2A. Number of sera from SLE patients with high or low anti-C1q and anti-MBL levels during 
inactive and active phases of disease
Table 2B. The mean antibody level of anti-MBL and anti-C1q per patient measured in sera 
from SLE patients with or without renal involvement
Number of sera with Number of sera with
high or low anti-C1q levels high or low anti-MBL levels
Disease activity >90 aU/ml <90 aU/ml >100 aU/ml <100aU/ml
Inactive 17 13 15 17 
Active 34 4 22 14 
Fisher exact test P=0.005 Fisher exact test P=0.3
The value for high levels of anti-MBL was set at a level at which te10% percent of the healthy control group were considered as
having high anti-MBL levels. Thereb, anti-MBL levels >100 aU/ml were defined as high.
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Figure 3. Biochemical characterisation of anti-MBL autoantibodies
After gel filtration, on a Superdex HR 20,0 of serum from a patient with SLE, fractions were
analysed for the presence of IgG anti-MBL ( indicated by the closed circles). The protein pat-
tern, as well as the position of filtration of  IgM, dimeric IgA (di-IgA), monomeric IgA (mo-
IgA)  and IgG are depicted (A). Anti-MBL reactivity was detected in serial dilutions of whole
serum (B, C) and purified F(ab')2 fragments (D) and (E), using antibodies against the light 
chains (B) and (D) and the Fc portion (mAb HB43) (C) and (E), respectively. 
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The data presented above indicate that IgG autoantibodies directed against MBL are
present in patients with SLE, but are not clearly associated with disease activity in the
patients examined in the present study.
Biochemical characterisation of anti-MBL autoantibodies
To examine whether binding of anti-MBL antibodies to MBL occurs via the antigen
recognition domain of IgG, we studied the antibody in more detail. Serum containing
anti-MBL antibodies was fractionated using a gel filtration column. The elution positi-
on of IgG, IgA, and IgM was assessed by ELISA (Fig. 3A). Anti-MBL IgG antibodies co-
eluted from the column with monomeric IgG, thus excluding that IgG which binds to
MBL is part of a larger (immune-) complex. No binding of IgM and IgA to MBL was
observed (data not shown). 
Figure 4 Interaction of anti-MBL with MBL in vivo
The mean MBL concentration per patient is shown in serum samples of 20 patients with SLE
and in 70 samples of healthy controls (A) Statistical analysis was performed on the mean MBL
level of the different serum samples from one patient. The correlation between anti-MBL levels
and ratio between the MBL complex activity and the MBL concentration is shown (B). For 
detection of complexes between IgG and MBL in serum, plates were coated with mAb anti-
MBL or control mAb, as indicated, and incubated with serial dilutions of an SLE serum con-
taining anti-MBL antibodies, followed by detection of IgG binding (C). The number of circu-
lating complexes between IgG and MBL in serum samples from patients with SLE and con-
trols (D). aU, arbitrary units.
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To analyse the binding site of IgG involved in the binding to MBL, F(ab')2 fragments
were generated from IgG isolated from pooled serum of patients with SLE with known
reactivity against MBL, as well as from IgG of healthy donors without anti-MBL auto-
antibodies, using pepsin digestion. Using a polyclonal antibody against kappa and
lambda light chains (Fig 3B) or a monoclonal antibody directed against the Fc portion
of IgG (HB43) (Fig 3C), it iwasdemonstrated that IgG from the SLE serum, but not IgG
from the control serum, binds dose-dependently to coated MBL. A strong dose-depen-
dent binding of F(ab')2 fragments from SLE serum but not of control F(ab')2 fragments
was demonstrated to MBL, using the polyclonal anti-light chain antibody (fig 3D). In
contrast, binding of the Fc portion of IgG anti-MBL was not detectable after digestion
of IgG (fig 3E) indicating the complete digestion of IgG. Binding of F(ab')2 fragments
to MBL strongly  suggests specific recognition of MBL by the antigen recognition
domain. 
Anti-MBL autoantibodies are found in complex with circulating MBL and are asso-
ciated with decreased MBL function
We investigated the influence of  anti-MBL autoantibodies on the function of circula-
ting MBL. It is conceivable that anti-MBL may affect the circulating MBL concentrati-
on. Patients with SLE had significantly higher MBL concentrations compared to healt-
hy controls (P=0.04) (Fig. 4A). No significant difference was found between samples
obtained during an inactive or active phase of disease (median MBL concentration
2175 ng/ml and 2802 ng/ml respectively, (P=0.20)). Levels of anti-MBL autoantibodies
were higher in patients with high serum levels of MBL (R=0.26, P=0,002). We further
assessed whether the anti-MBL antibodies influence the MBL complex activity. As
expected [34], a strong correlation between the MBL serum concentration and the MBL
complex activity was found (R = 0.65, P < 0.0001). A negative correlation was found
between  anti-MBL antibody levels and MBL complex activity adjusted for MBL con-
centration (Fig 4B). These data indicate a reduced functional activity of circulating
Anti-C1q
>90 aU/ml <90 aU/ml
Anti-MBL >100 aU/ml 33 4 
<100 aU/ml 18 13 
Fisher exact test P=0.05
Table 3. Number of serum samples from patients with high or low levels 
of anti-C1q and anti-MBL antibodies
aU, arbitrary units. 
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MBL-MASP complexes in the presence of anti-MBL autoantibodies. To examine whe-
ther IgG is bound to circulating MBL in vivo, we examined the presence of complexes
between MBL and IgG in ELISA. A strong dose-dependent binding of IgG-MBL com-
plexes was observed following the incubation of SLE patient serum to wells coated
with mAb anti-MBL, but not to well coated with a mAb of irrelevant specificity (Fig.
4C). Further analysis of the presence of these complexes revealed strongly enhanced
levels of IgG-MBL complexes in patients with SLE as compared to healthy controls
(Fig. 4D, P <0.001). The level of these complexes was positively correlated with anti-
MBL levels (R=0.27, P<0.001) and negatively correlated with the functional activity of
MBL (R=-0.17, P=0.04) Together, these data suggest that IgG anti-MBL antibodies inter-
act with MBL in vivo. 
Discussion
In the present study we demonstrate the presence of anti-MBL autoantibodies in
patients with SLE. The data suggest an effect of anti-MBL antibodies on the MBL com-
plex activity of circulating MBL. The presence of anti-MBL antibodies did not result in
a decrease of the MBL serum concentration. MBL, a member of the collectin family, is
a major recognition unit in the most recently described pathway of complement acti-
vation. Collectins are proteins with a C-type lectin domain structurally related to C1q,
the first component of the classical pathway of complement activation. Binding of
MBL to carbohydrates on certain microbial surfaces can activate the complement sys-
tem and mediate phagocytosis through receptors on phagocytes. However binding of
C1q to carbohydrate structures has not been found.
The importance of the complement system in the pathogenesis of SLE is recognised in
different, contrasting, ways.  On the one hand activation of complement by immune
complexes, deposited in tissue, leads to tissue damage. On the other hand, deficiencies
of (particularly) the early complement proteins of the classical pathway are associated
with SLE.  Furthermore, presence of autoantibodies to neoepitopes on C1q, exposed
upon binding to surfaces, is found in one-third of patients with SLE and is associated
with renal involvement and hypocomplementaemia [36].
Apoptosis and the role of complement in the clearance of apoptotic material has been
implicated in the pathogenesis of SLE [37].  Increased circulating levels of apoptotic
material have been demonstrated in patients with SLE [38]. Binding of C1q and MBL
to apoptotic products has been postulated to play a role in the clearance of apoptotic
debris via phagocytosis [39,40].  Furthermore autoantibodies associated with SLE are
reactive with this apoptotic material [41]. An increased production, and decreased and
aberrant clearance, of apoptotic material might cause autoantibody production to anti-
gens present on this material. Because of the presence of C1q on these apoptotic cells,
this might also be true for generating anti-C1q antibodies. In recent literature binding
of MBL to apoptotic material has clearly been shown [42]. Hence, it is possible that
because of a greater quantity of apoptotic material in sera of patients with SLE, and a
possible less efficient clearance of this material, autoantibodies are formed against
MBL present on apoptotic cells. 
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We assessed the presence of  anti-MBL autoantibodies in 68 sera of patients with SLE
during inactive and active phase of disease. A highly significant difference was found
between the anti-MBL levels in patients with SLE and those in healthy subjects.
Because anti-C1q levels are strongly correlated to active kidney disease in SLE, we
investigated whether the increased anti-MBL levels in patients with SLE were attribu-
ted to disease activity. We found no difference between anti-MBL levels in sera of
patients with active disease and inactive disease. As expected, the levels of anti-C1q in
the different sera obtained during active disease were significantly higher than those
obtained during inactive disease. As we examined only a limited number of patients
in the present study, a definite conclusion on the importance of anti-MBL autoantibo-
dies for disease in patients with SLE can not be given and requires more extensive
investigations.
Because of the similarity of the collagen tails of C1q and MBL, a possible cross-reacti-
vity of the anti-C1q antibodies with MBL was considered. A positive correlation was
found between anti-MBL and anti-C1q levels in sera from patients with SLE. Therefore
one could speculate about the cross-reactivity of anti-C1q with MBL. On the other
hand, the presence of autoantibodies directed to a variety of antigens is typically found
in patients with SLE and therefore anti-C1q and anti-MBL could be directed against
different autoantigens. In four sera (6%) we found anti-MBL antibodies without anti-
C1q reactivity, suggestive for an anti-MBL specific antibody. This would be in agree-
ment with the findings of Martensson et al. [33] who found no cross-reactivity of anti-
C1q antibodies with MBL.
To examine the nature of anti-MBL autoantibodies, the interaction with MBL was stu-
died in greater detail. We demonstrated that MBL binding was a property of monome-
ric IgG. Binding to MBL was calcium-independent, as it was established in the presen-
ce of EDTA, thus excluding that carbohydrates present on IgG were binding to the C-
type lectin domain of MBL. Furthermore, using F(ab')2 fragments of IgG, we showed
that binding was localized in the antigen-recognition domain of IgG. These findings
strongly suggest that IgG binding to MBL represent a true antibody-antigen interacti-
on. 
During an active phase of renal involvement in SLE, the C1q levels are decreased
because of activation of the classical pathway of complement activation , triggered by
the interaction of C1q with immune complexes. A second cause for reduced  C1q levels
is the presence of anti-C1q antibodies. Genetic deficiency of C1q is strongly correlated
with the development of SLE. Association of reduced MBL levels (as a consequence of
gene polymorphisms) with SLE has been reported previously [23]. Anti-MBL antibo-
dies, similarly to anti-C1q antibodies, could be a cause of low MBL levels in patients
with SLE. Higher MBL levels were, however, found in the sera from patients with SLE.
A possible explanation could be an increase of MBL levels owing to an acute phase res-
ponse, although we found no significant difference in MBL levels in sera obtained
from patients during active or inactive phases of disease. Anti-MBL autoantibody
levels were higher in patients with high MBL concentrations, suggesting that these
autoantibodies do not contribute to increased MBL turnover. Possibly the presence of
anti-MBL antibodies, and higher concentrations of MBL, are both a result of disease
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activity. Furthermore, it could be that anti-MBL autoantibodies are preferentially gene-
rated in patients with higher MBL levels owing to an increased exposure of the immu-
ne system to (target-bound) MBL. 
We continued to examine the effect of the presence of anti-MBL autoantibodies on
MBL concentration and function. A significant, negative correlation was observed
between the levels of anti-MBL autoantibodies and the MBL complex activity of circu-
lating MBL. The latter parameter represents the ability of the MBL-MASP complexes
to activate C4, corrected for the MBL serum concentration. Therefore, the association
between anti-MBL antibodies and decreased MBL function suggests that these autoan-
tibodies can interfere with the MBL-MASP complex. Such an interference is conceiva-
ble in at least three different ways: first, anti-MBL antibodies may inhibit MBL binding
to mannan; second, these antibodies may interfere with the binding of MASP-2 to
MBL; and, third, anti-MBL antibodies may bind to the (ligand-bound) MBL-MASP
complex and prevent MASP-2 activation. A further argument for the interaction of
autoantibodies with  MBL in vivo is the presence of circulating complexes between
MBL and IgG found in the serum samples of patients with SLE in association with the
presence of IgG anti-MBL. A negative correlation between MBL complex activity and
circulating IgG-MBL complexes was found, supporting the suggestion that anti-MBL
antibodies bind to MBL in vivo. It is conceivable that these complexes actually are
released into the circulation after previous formation in the solid phase. Further expe-
riments are required to establish whether the interaction of IgG with MBL is indeed
involved in the association between the presence of anti-MBL antibodies and impaired
MBL function in vivo. 
To our knowledge this is the first report on the presence of anti-MBL autoantibodies in
serum from patients with SLE. As far as the results show we cannot predict activity of
disease by the presence of anti-MBL autoantibodies. Fascinatingly, these anti-MBL
autoantibodies are associated with decreased MBL function.  A greater number of
patients should be tested for reactivity against MBL before a final conclusion can be
made on the role of anti-MBL autoantibodies in the pathogenesis of SLE.
Acknowledgements
The authors thank Ngaisah Klar-Mohamad and Ria C. Faber-Krol for excellent techni-
cal assistance,  Dr. C.E. Hack (Amsterdam, The Netherlands) and Dr. T. Fujita
(Fukushima, Japan) for their kind gift of reagents used in this study and Dr. M.J.K.
Mallat for the statistical analysis of the data. Part of this work was supported by the
Dutch Kidney Foundation (PC 95).
66
Chapter 3
References
1. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-66.
2. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140-4.
3. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, 
complement deficiency, and apoptosis. Adv Immunol 2000; 76:227-324.
4. Gunnarsson I, Ronnelid J, Huang YH et al. Association between ongoing anti-C1q antibody pro-
duction in peripheral blood and proliferative nephritis in patients with active systemic lupus ery
thematosus. Br J Rheumatol 1997; 36:32-7.
5. Moroni G, Trendelenburg M, Del Papa N et al. Anti-C1q antibodies may help in diagnosing a renal
flare in lupus nephritis. Am J Kidney Dis 2001; 37:490-8.
6. Siegert C, Daha M, Westedt ML, van d, V, Breedveld F. IgG autoantibodies against C1q are correla-
ted with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus.
J Rheumatol 1991; 18:230-4.
7. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA. Lack of occurrence of severe lupus 
nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1999; 42:187-8.
8. Davies EJ, Snowden N, Hillarby MC et al. Mannose-binding protein gene polymorphism in system-
ic lupus erythematosus. Arthritis Rheum 1995; 38:110-4.
9. Turner MW. Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998; 199:327-39.
10. Hansen S, Holmskov U. Structural aspects of collectins and receptors for collectins. Immunobiology
1998; 199:165-89.
11. Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T. Proteolytic activities of two types of mannose-
binding lectin-associated serine protease. J Immunol 2000; 165:2637-42.
12. Garred P, Thiel S, Madsen HO, Ryder LP, Jensenius JC, Svejgaard A. Gene frequency and partial pro-
tein characterization of an allelic variant of mannan binding protein associated with low serum con-
centrations. Clin Exp Immunol 1992; 90:517-21.
13. Madsen HO, Garred P, Kurtzhals JA et al. A new frequent allele is the missing link in the structural
polymorphism of the human mannan-binding protein. Immunogenetics 1994; 40:37-44.
14. Sumiya M, Super M, Tabona P et al . Molecular basis of opsonic defect in immunodeficient children.
Lancet 1991; 337:1569-70.
15. Lipscombe RJ, Sumiya M, Hill AV et al. High frequencies in African and non-African populations of
independent mutations in the mannose binding protein gene. Hum Mol Genet 1992; 1:709-15.
16. Madsen HO, Garred P, Thiel S et al. Interplay between promoter and structural gene variants con-
trol basal serum level of mannan-binding protein. J Immunol 1995; 155:3013-20.
17. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low pro
tein levels of mannan-binding lectin in populations from southeast Africa and South America. J 
Immunol 1998; 161:3169-75.
18. Richardson VF, Larcher VF, Price JF. A common congenital immunodeficiency predisposing to infec-
tion and atopy in infancy. Arch Dis Child 1983; 58:799-802.
67
Chapter 3
19. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding 
protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314:1229-32.
20. Koch A, Melbye M, Sorensen P et al. Acute respiratory tract infections and mannose-binding lectin
insufficiency during early childhood. JAMA 2001; 285:1316-21.
21. Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding
lectin and severe infections after chemotherapy. Lancet 2001; 358:637-8.
22. Davies EJ, Teh LS, Ordi-Ros J et al. A dysfunctional allele of the mannose binding protein gene asso-
ciates with systemic lupus erythematosus in a Spanish population. J Rheumatol 1997; 24:485-8.
23. Garred P, Voss A, Madsen HO et al . Association of mannose-binding lectin gene variation with 
disease severity and infections in a population-based cohort of systemic lupus erythematosus 
patients. Genes Immun 2001; 2:442-50.
24. Ip WK, Chan SY, Lau CS, Lau YL. Association of systemic lupus erythematosus with promoter poly
morphisms of the mannose-binding lectin gene. Arthritis Rheum 1998; 41:1663-8.
25. Sullivan KE, Wooten C, Goldman D, Petri M. Mannose-binding protein genetic polymorphisms in 
black patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:2046-51.
26. Villarreal J, Crosdale D, Ollier W et al. Mannose binding lectin and FcgammaRIIa (CD32) polymor-
phism in Spanish systemic lupus erythematosus patients. Rheumatology (Oxford) 2001;  40:1009-12.
27. Tsutsumi A, Sasaki K, Wakamiya N et al. Mannose-binding lectin gene: polymorphisms in Japanese
patients with systemic lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome. Genes 
Immun 2001; 2:99-104.
28. Huang YF, Wang W, Han JY et al. Increased frequency of the mannose-binding lectin LX haplotype
in Chinese systemic lupus erythematosus patients. Eur J Immunogenet 2003; 30:121-4.
29. Garred P, Madsen HO, Halberg P et al. Mannose-binding lectin polymorphisms and susceptibility 
to infection in systemic lupus erythematosus. Arthritis Rheum 1999; 42:2145-52.
30. Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR. Glomerular deposition
of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp 
Immunol 2003; 132:32-9.
31. Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC. Predictive value of IgG 
autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 
52:851-6.
32. Roos A, Bouwman LH, Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA acti-
vates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167:2861-8.
33. Martensson U, Thiel S, Jensenius JC, Sjoholm AG. Human autoantibodies against Clq: lack of cross
reactivity with the collectins mannan-binding protein, lung surfactant protein A and bovine conglu-
tinin. Scand J Immunol 1996; 43:314-20.
34. Petersen SV, Thiel S, Jensen L, Steffensen R, Jensenius JC. An assay for the mannan-binding lectin 
pathway of complement activation. J Immunol Methods 2001; 257:107-16.
35. Antes U, Heinz HP, Loos M. Evidence for the presence of autoantibodies to the collagen-like por-
tion of C1q in systemic lupus erythematosus. Arthritis Rheum 1988; 31:457-64.
68
Chapter 3
36. Coremans IE, Spronk PE, Bootsma H et al. Changes in antibodies to C1q predict renal relapses in 
systemic lupus erythematosus. Am J Kidney Dis 1995; 26:595-601.
37. Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement proteins
in the clearance of apoptotic cells in vivo. J Exp Med 2000; 192:359-66.
38. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with sys-
temic lupus erythematosus. J Immunol 1994; 152:3685-92.
39. Nauta AJ, Trouw LA, Daha MR et al . Direct binding of C1q to apoptotic cells and cell blebs induces
complement activation. Eur J Immunol 2002; 32:1726-36.
40. Nauta AJ, Daha MR, Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for com-
plement and pentraxins. Trends Immunol 2003; 24:148-54.
41. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apopto-
tic cells by human macrophages. J Exp Med 1998; 188:2313-20.
42. Ogden CA, deCathelineau A, Hoffmann PR et al. C1q and mannose binding lectin engagement of 
cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp 
Med 2001; 194:781-9
69
Chapter 4
A role for mannose-binding lectin dysfunction
in generation of autoantibodies
in systemic lupus erythematosus
Marc A Seelen , Egon A van der Bijl , Leendert A Trouw, Tahlita CM Zuiverloon,
Jeric R Munoz , Francien C Fallaux-van den Houten, Nicole Schlagwein,
Mohamed R Daha, Tom WJ Huizinga, Anja Roos
Department of Nephrology and Rheumatology, Leiden University Medical Center,
Leiden, The Netherlands.
Rheumatology  44 (2005) 111-119
70
Chapter 4
Objective. To investigate the possible association of the mannose binding lectin  (MBL)-
pathway of complement activation with different disease parameters and disease acti-
vity in patients with systemic lupus erythematosus (SLE).
Methods. MBL genotype, MBL serum concentration, MBL complex activity and MBL-
pathway activity were assessed in 53 patients. The activity of the MBL-MASP complex
was assessed on basis of its ability to activate exogenous C4. For MBL-pathway activi-
ty the formation of the terminal complex of complement activation (C5b-9) was mea-
sured. Results were analysed in relation to clinical variables and autoantibody profiles
in these patients.  
Results. MBL complex activity and MBL-pathway activity were both reduced in
patients carrying MBL variant alleles. Anti-cardiolipin and anti-C1q autoantibodies
were observed significantly more frequently in patients with MBL variant alleles.
Furthermore, the presence of these autoantibodies was associated with a decreased
MBL concentration and function. In contrast, anti-MBL autoantibodies were not found
in patients with MBL variant alleles, possibly related to impaired binding of variant
MBL to apoptotic material. 
Conclusion. In patients with SLE, a reduced functional activity of the MBL-pathway of
complement, in relation to expression of MBL variant alleles, is associated with increa-
sed levels of autoantibodies against cardiolipin and C1q, but not against MBL. We
hypothesize that an enhanced production of autoantibodies may be related to distur-
bed clearance of apoptotic material due to impaired MBL function. 
Introduction
Susceptibility to systemic lupus erythematosus (SLE) is related to genetic as well as
environmental factors. It is thought that a combination of genes, rather than a single
gene, predisposes to the development of SLE. Many genes have been reported to be
linked with the development of spontaneous SLE, including several loci encoding dif-
ferent complement components and complement receptors [1]. Genetic deficiencies of
complement components, especially of the early components of the classical pathway,
are strongly associated with the occurrence of SLE [2]. In this respect, the genetic asso-
ciation between deficiency of C1q, the recognition factor of the classical complement
activation pathway, with SLE is nearly 100 %. This association between C1q deficien-
cy and systemic autoimmunity has been linked to a role for C1q in recognition and
clearance of apoptotic material [3,4]. Defective clearance and increased generation of
apoptotic material has been demonstrated in patients with SLE [5]. Furthermore, auto-
antibodies found in patients with SLE are mostly directed against antigens present on
apoptotic material [6]. 
Recent studies indicate also a possible role for the lectin pathway of complement acti-
vation in the pathogenesis of SLE [7]. Variant alleles leading to reduced serum concen-
trations of mannose-binding lectin (MBL) are associated with a predisposition for SLE
[8-11]. MBL is a major recognition factor of the lectin pathway of complement. The
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molecule is composed of trimeric subunits assembled to higher order structures con-
sisting of up to six trimers. This structure resembles the bouquet-like structure of C1q
[12]. Also the MBL-associated serine proteases MASP-1, MASP-2 and MASP-3 are
functionally related to the serine proteases of the classical pathway, C1r and C1s. After
binding of the calcium-dependent carbohydrate recognition domain of MBL to diffe-
rent carbohydrates, activation of the complement cascade can take place [13]. MBL is
able to bind to apoptotic cell debris via its lectin domain, which is involved in the pha-
gocytosis of apoptotic cells by macrophages [14,15]. Since MBL has been postulated to
play a role in the clearance of apoptotic material [3], this mechanism could provide a
possible explanation for the association between MBL deficiency and the occurrence of
SLE. 
MBL deficiency or low serum MBL levels are frequently found in the general popula-
tion due to single nucleotide polymorphisms (SNPs) in the structural portion or pro-
moter region of the mbl2 gene [7,12,16]. Three SNPs have been identified in the struc-
tural domain of the MBL gene, located in codon 52 [17], 54 [18] and 57 [19] of exon 1,
whereas additional SNPs exist upstream of the MBL gene at position -550 (H/L alleles),
-221 (X/Y alleles) and  +4 (P/Q alleles) [20,21]. The occurrence of these SNPs in the MBL
gene are associated with predisposition for the development of SLE and with compli-
cations caused by bacterial infections in patients with SLE [8,10,22].  Furthermore, a
tendency towards more renal disorders in SLE patients with MBL variant alleles has
been reported [8].
Studies on the association of MBL and SLE until now have focused on MBL genotype
and MBL concentration. In the present study, we examined whether functional impair-
ment of the MBL-pathway is associated with parameters of disease activity. The results
indicate that MBL gene polymorphisms, low MBL concentration and impaired functio-
nal activity of the MBL pathway are associated with the presence of anti-cardiolipin
and anti-C1q antibodies in patients diagnosed with SLE. 
Patients and Methods
Patients
Fifty three patients with a mean age of 39 years made up of 92% females all fulfilling
at least 4 American College of Rheumatology criteria for SLE were included in this
study. The patients visited the out-patient clinic of the Rheumatology department at
the Leiden University Medical Center from 1997 to 1998. The median disease activity
in these patients was 4.3 (0-18) as measured with the SLE Disease Activity Index (SLE-
DAI), and organ damage measured with the Systemic Lupus International
Collaborating Clinics/ACR Damage Index found in the patient group was 2 (1-4.5).
Informed consent was obtained from all patients. The clinical and laboratory variables
tested were the following: the ACR criteria for SLE (skin rash, photosensitivity, oral
ulcers, renal involvement, joint involvement, serositis, neurological disorders, haema-
tologic disorders and autoantibody profile), age at disease onset, SLE Disease Activity
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Index (SLEDAI), and SLE damage index adjusted for years of disease. Paired serum
and DNA samples were available. 
PCR amplification of exon 1 of the MBL gene and oligonucleotide ligation assay
(OLA) for MBL genotyping
MBL genotyping was performed using genomic DNA from SLE patients (N = 53) and
from a population of healthy Caucasian controls (N = 59). Exon 1 of the MBL gene was
amplified from genomic DNA by PCR. Detection of MBL-mutant alleles at codon 52,
54 and 57 were carried out with three different oligonucleotide ligation assays (OLA).
The PCR amplification and OLA were performed exactly following the procedure as
described before [23]. 
Measurement of MBL serum concentrations
MBL concentrations in serum were assessed precisely as described previously [24].
Functional activity of the MBL complex
The assessment of activity of MBL and its associated serine proteases (MBL complex
activity) was performed using a slightly modified method as described by Petersen et
al. [25]. In brief, mannan-coated plates were incubated for 16 hours at 4 °C with serum,
diluted in GVB++  containing 1 M NaCl. Plates were washed with PBS/Tween contai-
ning 5 mM CaCl2, followed by incubation with purified C4 (1 µg/ml), diluted in VBS
containing 1 mM MgCl2, 2 mM CaCl2, 0.05 % Tween-20, and 1 % BSA, pH 7.5, for 1
hour at 37 °C. Binding of activated C4 was assessed using mAb C4-4a (anti-human
C4d, from Dr. C.E. Hack, Amsterdam, The Netherlands) conjugated to dig, followed
by HRP-conjugated sheep anti-dig antibodies as described above. MBL-complex acti-
vity was expressed in arbitrary units per ml, based on serial dilutions of a human pool-
serum that was used as a standard on each plate. Activity of this standard was set at
1,000 U/ml.
Functional activity of the whole MBL-pathway
The functional activity of the MBL-pathway in whole serum, from MBL binding to
mannan up to the deposition of C5-9, was assessed by ELISA [23]. 
Plates (Nunc Maxisorb, Nunc, Roskilde, Denmark) were coated with mannan
(100µg/ml, from Saccharomyces cerevisiae; Sigma, St. Louis, MO) in coating buffer
(100 mM Na2CO3/NaHCO3, pH 9.6), for 2 h at 37 °C. After each step, plates were was-
hed three times with PBS containing 0.05% Tween-20. Residual binding sites were
blocked by incubation with PBS containing 1% BSA for 1 h at 37 °C. Next, serum sam-
ples were diluted in GVB++ (VBS (1.8 mM Na-5,5-diethylbarbital, 0.2 mM 5,5-diethyl-
barbituric acid, 145 mM NaCl) containing 0.5 mM MgCl2, 2 mM CaCl2, 0.05% Tween-
20, and 0.1% gelatin; pH 7.5) in the presence of mAb 2204 (20 µg/ml) as an inhibitor of
C1q, to exclude contribution of the classical pathway via antibodies reactive with man-
nan. This mixture was pre-incubated for 15 min on ice, before addition to the plates.
The plates were then sequentially incubated for 1 h at 4 °C and for 1 h at 37 °C. The
amount of C5b-9 generated, as a measure of MBL pathway activation, was detected
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with mouse mAb AE11 (anti-human C5b-9, kindly provided by Dr. T.E. Mollnes, Oslo,
Norway) conjugated to digoxygenin-3-O-methylcarbonyl-rounded e-aminocaproic
acid-N-hydroxysuccinimide ester (dig) (from Boehringer Mannheim, Mannheim,
Germany). The degree of binding of mAb was subsequently detected using dig-conju-
gated sheep anti-mouse antibodies (Fab fragments) followed by HRP-conjugated
sheep anti-dig antibodies (Fab fragments, both from Boehringer Mannheim Germany).
Enzyme activity of HRP was detected following incubation with 2,2'-azino-bis(3-ethyl-
benzthiazoline-6-sulfonic acid) (from Sigma; 2.5 mg/ml in 0.1 M Citrate/Na2HPO4 buf-
fer, pH 4.2) in the presence of 0.01% H2O2, for 30-60 min at room temperature. The OD
at 415 nm was measured using a microplate biokinetics reader (EL312e, from Biotek
Instruments, Winooski, VT, USA). Functional activity of the MBL-pathway was
expressed in units per ml, relative to a positive standard consisting of pooled human
serum arbitrarily set at 1,000 U/ml.
Functional activity of the classical pathway
Classical pathway activity was assessed by determining C4 activation on immobilised
IgM using an ELISA-based procedure as described by Roos et al. [23].
Detection of antibodies against C1q, MBL, DNA and anti-cardiolipin.
Anti-C1q autoantibodies were assessed as described [26]. A recently described method
to detect anti-MBL antibodies was used to determine MBL-Abs [27].
Antibodies against DNA were measured using an immunofluorescent method as des-
cribed by Aarden et al (28). Antibodies against cardiolipin were measured using a
commercially available Varelisa Cardiolipin IgG antibodies kit (Pharmacia diagnostics,
Germany).
Statistics
The Mann-Whitney test and the Chi-square test were used for statistical analysis.
Correlation was evaluated using the Spearman Rank correlation coefficient. P values
less than 0.05 were considered statistically significant.
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Results
MBL genotype from patients in relation to disease expression
All 53 patients were genotyped for MBL variant alleles at codon 52 (named D), at
codon 54 (named B) and at codon 57 (named C) of exon 1 of the mbl2 gene. The wild-
type genotype (A/A) was observed in 37 out of the 53 patients (70%), the A/B genoty-
pe was found in 4 patients, 5 patients carried the A/C genotype and 5 patients the A/D
genoype, whereas the B/B and D/C genotype were both found in 1 patient. This geno-
type distribution was compared to a population of healthy Caucasian controls. Both in
the Caucasian SLE patients (N = 44) and in the healthy controls (N = 59), 66 % expres-
sed the wildtype genotype (A/A). 
We divided the patients with SLE in two groups: one group with the wildtype geno-
type (A/A) and one group of carriers of variant alleles (A/0 or 0/0 genotype). Because
of the limited number of patients with the 0/0 allele it was not possible to study these
patients as an independent group. The frequencies of the different clinical variables
and MBL genotype distribution in the two patient groups are shown in table 1. No dif-
ference was observed between carriers of wildtype alleles (A/A) and variant alleles
(non-A/A) in clinical presentation of the disease variables. In contrast, significant dif-
ferences were noted between carriers of MBL wildtype alleles and MBL variant alleles
Clinical variables Number of
Patients
a
(total=53)
(%) Genotype A/A
(N=37)
Genotype A/0 or 0/0
(N=16)
P
Value
b
present absent present absent
Malar rash 11 21 9 26 2 14 ns
Ulcers 22 42 15 20 7 9 ns
Arthritis 26 49 17 19 9 7 ns
Serositis 41 77 27 7 14 2 ns
Renal involvement 25 47 17 20 8 8 ns
Neurologic involvement 18 34 12 25 6 10 ns
Haematologic involvement 23 43 15 22 8 8 ns
Thrombosis 4 8 2 35 2 14 ns
a. Indicated are the number (percentage ) of patients with clinical or laboratory findings of disease activity at the
moment the serum samples were taken.
b. The association between MBL genotype and clinical variables was tested by a Chi-square test.
Table 1. Clinical variables and MBL genotype distribution in patients with SLE. 
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with respect to the autoantibody profile. A significant difference was observed concer-
ning the presence of anti-cardiolipin antibodies and anti-C1q antibodies:  autoantibo-
dies against cardiolipin and against C1q were significantly associated with the occur-
rence of MBL gene polymorphisms (Table 2). In contrast, there was a trend towards a
lower presence of anti-MBL autoantibodies in SLE patients with variant alleles.
Genotype A/A
(N=37)
Genotype A/0 or 0/0
(N=16)
P
Value
Autoantibody specificity  present absent present absent
         Anti-dsDNA 23 14 9 7 0.69 
       Lupus anti-coagulant 4 31 4 12 0.2 
         Anti-cardiolipin 10 25 10 6 0.03 
         Anti-C1q 3 34 5 9 0.03 
         Anti-MBL 7 29 0 15 0.066 
Table 2. The presence or absence of different autoantibodies in SLE patients with wild type MBL
genotype and variant MBL genotype.
Functional characterisation of the MBL pathway in SLE
The impact of MBL gene polymorphisms on MBL protein expression and function in
SLE patients was examined using three different parameters, namely MBL serum con-
centration, MBL complex activity and MBL pathway activity.  
The MBL concentrations in all sera were assessed by ELISA (Fig 1A). The MBL concen-
tration in the sera from SLE patients with the A/A genotype varied from 0.3 ng/ml to
3.8 µg/ml (N = 34, median 0.829 µg/ml). The MBL concentrations in sera from patients
with variant alleles were significantly decreased as expected (median 0.279 µg/ml, N =
14, P= 0.0002). To demonstrate the functional activity of the complex of MBL with the
associated MASPs, activation of exogenous C4 by MBL complexes bound to mannan
was assessed in an MBL complex activity assay (Fig 1B). The activity of the MBL com-
plex varied from 425 aU/ml to 3,930 aU/ml (median 1,497 aU/ml) in the patients with
a wildtype MBL genotype and a significantly decreased activity was found in sera
from patients with a variant allele (median 371 aU/ml, P= 0.0003). For the activity of
the MBL pathway in full serum an ELISA was used measuring the formation of the ter-
minal complex (C5b-9) via autologous complement components on solid phase man-
nan. The activity of the complete MBL-pathway in SLE patients with a wildtype MBL
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genotype varied from undetectable (below 350) until 2,126 aU/ml (median  808 aU/ml),
which is significantly different from the decreased activity found in carriers of variant
alleles (median 467 aU/ml, P= 0.0036) (Fig 1C). Also the classical pathway activity was
assessed in the same sera. No difference was found in classical pathway activity
between patients with wildtype MBL genotype and patients with a variant allele (Fig
1D). Both the MBL complex activity and the MBL-pathway activity showed a signifi-
cant correlation with the MBL concentration (R = 0.82; P < 0.001, and R = 0.65; P < 0.001,
respectively (Fig. 2)). However, several serum samples showed a low or undetectable
MBL-pathway activity whereas the MBL concentration and the MBL complex activity
were in the normal range (Fig. 2B). MBL-pathway activity showed a significant corre-
lation with the classical pathway activity (R = 0.41; P = 0.004) (Fig 2C), whereas MBL
concentration was not correlated to classical pathway activity (R = 0.02, P = 0.91).
Functional activity of the MBL pathway in relation to disease
We analysed the MBL concentration, MBL complex activity and MBL-pathway activi-
ty for possible association with the different clinical variables. No significant associa-
tion between the different clinical variables and MBL concentration or functional acti-
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Figure 1. MBL function and classical pathway activity in relation to MBL genotype. The MBL genoty-
pe from 53 patients with SLE was determined. MBL concentration (A), MBL complex activi
ty (B),MBL pathway activity (C) and classical pathway activity (D) was assessed in sera from
patients with the different MBL genotypes. A significant difference was found when MBL con
centration (P= 0.0002), MBL complex activity (P=0.0003) and MBL pathway activity 
(P=0.0036) in patients with wildtype MBL were compared with patients carrying variant alle-
les (Mann Whitney test). The dotted lines indicate the detection limit of the assay.
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MBL function in relation to MBL
concentration and classical path-
way activity. 
The correlation of MBL concen-
tration and MBL complex activity
(A) as well as the correlation
between MBL concentration and
MBL pathway activity (B) is
shown for different sera from SLE
patients carrying wildtype or
variant alleles as indicated. The
correlation between MBL path-
way activity and classical path-
way activity is shown for the same
sera (C).  The dotted lines indica-
te the detection limit of the assay. .
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vity was found. However, significantly lower MBL concentrations (Fig 3A, P = 0.03),
MBL complex activity (Fig 3B, P = 0.03) and MBL pathway activity (Fig. 3C, P = 0.02)
was found in patients with anti-C1q antibodies as compared to patients without these
autoantibodies. Similarly, the presence of anti-cardiolipin autoantibodies was associa-
ted with low serum levels of MBL (Fig. 3D, P = 0.01), low MBL complex activity (Fig.
3E, P = 0.02) and low MBL pathway activity (Fig. 3F, P = 0.03). In sharp contrast to these
findings, patients with autoantibodies against MBL in their serum had significantly
higher MBL concentrations (p= 0.025) (Fig 3G). A similar but non-significant trend was
found for MBL complex activity (P = 0.07) whereas MBL pathway activity was not sig-
nificantly different between patients with or without anti-MBL autoantibodies (Fig 3
H and I). No significant association was found between the presences of autoantibo-
dies and classical pathway activity (P > 0.28; data not shown). Together, these data
demonstrate an association of autoantibodies against cardiolipin and C1q with MBL
dysfunction.
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Figure 3. The presence of autoantibodies is associated with MBL concentration and function. 
Sera from SLE patients were dived into two groups on basis of the absence or presence of auto
antibodies against C1q (A-C), cardiolipin (D-F) and MBL (G-I). MBL concentration, MBL
complex activity and MBL pathway activity in the different sera is shown for each group. 
Differences between the two groups were evaluated by the Mann Whitney test.
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MBL genotype and function in relation to SLE disease activity
In order to examine whether MBL pathway dysfunction is also related to disease acti-
vity we analysed the SLE Disease Activity Index (SLEDAI) in SLE patients divided in
two groups on basis of the MBL genotype, the MBL concentration, the MBL complex
activity, and the MBL- pathway activity, respectively. 
Disease activity was not significantly different between patients with MBL wildtype or
variant alleles, between patients with high or low MBL concentration and between
patients with high or low MBL complex activity (Fig. 4 A-C). However, patients with
low MBL-pathway activity (< 500 aU/ml) had significantly more disease activity, mea-
sured with the SLE Disease Activity Index (SLEDAI), compared to patients with high
(> 500 aU/ml) MBL-pathway activity (Fig 4D). No significant difference was found
between SLEDAI of patients with high or low classical pathway activity (P = 0.25; data
not shown). The MBL genotype, MBL concentration, MBL complex activity or MBL-
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Figure 4. SLE disease activity in relation to MBL genotype and function. SLE disease activity indexes
(SLEDAI) are shown for SLE patients carrying wildtype MBL genotype or variant alleles (A),
and low or high levels of MBL concentration, MBL complex activity and MBL pathway acti-
vity (B-D), respectively, as indicated.
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pathway activity were not significantly associated with organ damage measured with
the Systemic Lupus International Collaborating Clinics/ACR Damage Index.
Discussion
The present study demonstrates in patients with SLE a significant association of the
presence of anti-cardiolipin and anti-C1q autoantibodies with the presence of MBL
variant alleles, with low serum MBL concentrations, and with impaired MBL function.
The results further indicate that expression of MBL variant alleles in SLE patients is not
only associated with reduced MBL concentrations but also with impaired MBL com-
plex activity and impaired MBL pathway activity. 
The presence of a wide variety of autoantibodies is a characteristic finding in SLE.
Most of the autoantibodies are directed against membranous, intracellular or nuclear
target antigens. Some antibodies are directed against fluid phase proteins such as C1q
[29] and MBL [27]. Autoantibodies against nuclear proteins, such as anti-nuclear
(ANA) and anti-dsDNA antibodies, are used as diagnostic markers in SLE [30], whe-
reas anti-C1q and anti-dsDNA antibodies are also used to monitor lupus activity. A rise
in the titer of anti-C1q antibodies is reported to be predictive for renal flares [31]. In
patients with SLE, impaired normal mechanisms of waste-disposal due to complement
deficiency have been hypothesised, and therefore this material can be a source of auto-
antigens. 
Recently it has been shown that MBL binds to apoptotic material and mediates its clea-
rance by macrophages [3,14,15]. Therefore, patients with low MBL serum concentrati-
ons and impaired MBL function could have a decreased rate of clearance of apoptotic
material, which may result into higher autoantibody levels directed against target anti-
gens, such as phosopholipids and C1q, present on apoptotic material. In contrast to
previously published results by Garcia-Laorden et al. [32], in our study anti-cardioli-
pin antibodies were more frequently found in patients with MBL variant alleles com-
pared to patients with MBL wildtype genotype. In addition, we demonstrated that C1q
autoantibodies are more frequently present in patients with MBL variant alleles, and
decreased MBL concentrations and impaired MBL activity were found in patients with
autoantibodies against C1q and cardiolipin. These findings support our hypothesis of
increased generation of autoantibodies to antigens present on apoptotic material in
SLE patients with MBL dysfunction. Furthermore, increased MBL concentrations were
found in SLE patients with anti-MBL autoantibodies and anti-MBL autoantibodies
were not found in patients with variant alleles. These results could indicate that only
intact wildtype MBL can bind efficiently to apoptotic material and therefore be presen-
ted by antigen presenting cells. However, the clinical relevance of anti-MBL antibodies
in patients with SLE has to be demonstrated.
A genetic deficiency for C1q is almost always associated with SLE in humans.
However, C1q deficiency is very rare and therefore it is not a major cause for SLE in
the human population. In a recent meta-analysis by Garred et al.[33], it was observed
that the presence of MBL variant alleles (A/0 and 0/0) were associated with a signifi-
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cantly increased risk to develop SLE when the diagnosis of SLE was based on the ful-
filling of at least four ACR criteria. In our study we did not find such an association
although our patients were similarly defined. However, this is probably due to the size
of the patient cohort examined in the present study. It was proposed by Garred and
colleagues that the MBL2 gene is a disease modifier locus rather than a true disease sus-
ceptibility locus, being involved in accelerated progression of the disease. In this res-
pect, our study supports this idea by showing that MBL2 variant alleles are associated
with increased production of autoantibodies that are known to be associated with
disease manifestations in SLE. Furthermore, our study indicates for the first time an
association between the presence of autoantibodies in SLE patients and functional
impairment of the MBL pathway of complement, which supports the genetic studies
indicating a role for MBL in SLE. 
MBL serum concentrations are known to be dependent on MBL genotype. Individuals
with variant alleles have decreased MBL serum concentrations compared to serum
concentrations of individuals with wildtype MBL genotype. We show that SLE
patients with MBL variant alleles have less functionally active MBL as compared to
patients with wildtype MBL. This was demonstrated by an impaired ability to activa-
te exogenous C4 by MBL-MASP complexes bound to mannan, as well as by an impai-
red capacity to activate the whole complement cascade upon binding of MBL to man-
nan. Within the population carrying the wildtype MBL2 gene the concentration of
MBL also varies from very low to normal levels, which could be at least partially
explained by differences in promoter genotypes. Also differences in serum concentra-
tions for MASPs could play a role in the variable functional activity of MBL in carriers
of the MBL wildtype genotype [34]. Differences in functional activity of the whole
MBL-pathway within the population carrying the wildtype MBL genotype could be
due to differences in MBL and MASP concentrations as well as differences in concen-
trations of the other complement components. 
Therefore, we assessed MBL complex activity as well as whole MBL-pathway activity
and classical pathway activity to examine the role of the MBL pathway in more detail
in patients with SLE. The MBL complex activity and the MBL pathway activity were
both dependent on MBL genotype. Furthermore, a highly significant correlation was
found between MBL concentration and MBL complex activity without evidence for
MASP-2 deficiency [35]. Also a statistically significant correlation was found between
MBL concentrations and MBL-pathway activity. However, this relation was less pro-
found compared to the relation between MBL concentrations and MBL complex acti-
vity, and a few discordant samples were noticed. A possible explanation for this fin-
ding is complement consumption in patients with SLE. For a fully active MBL-
pathway appropriate serum complement concentrations are required. To further
investigate this possibility classical pathway activity was assessed in the same sam-
ples. Classical pathway activity was significantly correlated with MBL pathway activi-
ty but not associated with MBL genotype. Since this correlation was shown to be inde-
pendent of MBL, this is most likely due to differences in the levels of complement con-
sumption shared by the MBL pathway and classical pathway. Furthermore, in serum
samples from patients with wildtype MBL genotype with a remarkable discrepancy
between MBL complex activity and MBL pathway activity, low classical pathway acti-
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vity was found. Therefore one could speculate that some of the patients with lower
levels of MBL-pathway activity are those patients with more active disease. Indeed, for
the SLE patients examined in the present study an association was found between
disease activity and MBL-pathway activity, as a functional parameter of the whole
complement cascade starting from MBL binding to mannan. However, MBL complex
activity and MBL serum concentrations were not significantly associated with the
disease activity index, indicating that the association between MBL pathway activity
and SLEDAI cannot be solely explained by MBL deficiency. Therefore, these results
suggest that a combination of factors, such as possible defects at the level of MBL as
well as acquired defects at other levels of the cascade, could be critical in this respect.
These acquired defects may include decreased levels of C4 and/or C3, which are well
know to be associated with severe disease in patients with SLE [36].
The results of our study could implicate that patients with less functional MBL may
present with more severe disease because of impaired clearance of apoptotic material
and therefore enhanced antibody production. The combined presence of anti-cardioli-
pin and anti-C1q autoantibodies was strongly associated with increased disease acti-
vity in the present study (P = 0.006, not shown). In addition, it has been shown that SLE
patients with MBL variant alleles show higher incidence of infections [33]. Therefore,
the increased production of antibodies in SLE patients with MBL dysfunction could
possibly also be related to impaired MBL-dependent clearance of non-self antigens.
Active disease and therefore more complement consumption in patients with lower
MBL concentrations could further deteriorate MBL-pathway activity as well as classi-
cal pathway activity, thus enhancing the susceptibility to infections, and possibly also
the disturbed clearance of apoptotic material. In a recent study on the binding of MBL
to apoptotic cells, it was observed that complement activation by apoptotic cells is pre-
dominantly due to activation of the classical pathway and not the MBL pathway of
complement [5].
The present study supports a role for MBL as a disease modifier in patients with SLE.
Functional impairment of the MBL pathway of complement, which is common in the
human population, appears to be associated with enhanced production of autoantibo-
dies against C1q and cardiolipin. In view of the role of MBL and C1q in the recogniti-
on of self debris, MBL deficiency may lead to disturbed in vivo clearance of apoptotic
material, resulting into enhanced production of autoantibodies against antigens asso-
ciated with apoptotic material, including C1q. Binding of autoantibodies to apoptotic
cells could subsequently further modulate the response of phagocytic cells towards
phagocytosis of apoptotic cells [3], thus leading to an amplification of systemic auto-
immunity.
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Abstract
Primary defence against invading microorganisms depends on a functional innate
immune system and the complement system plays a major role in such immunity.
Deficiencies in one of the components of the complement system can cause severe and
recurrent infections, systemic diseases such as systemic lupus erythematosus (SLE)
and renal disease. Screening for complement deficiencies in the classical or alternative
complement pathways has mainly been performed by haemolytic assays. Here we des-
cribe a simple ELISA-based format for the evaluation of three pathways of comple-
ment activation. The assays are based on specific coatings for each pathway in combi-
nation with specific buffer systems. We have standardized these assays and defined
cut off values to detect complement deficiencies at the different levels of the comple-
ment system. The results demonstrate the value of these ELISA-based procedures for
the functional assessment of complement deficiencies in clinical practice. The assay is
now available commercially in kit form.
Introduction
The complement system has an essential role in innate immune defence and can be
activated by three different pathways (Walport 2001). The classical pathway is activa-
ted by binding of C1q to e.g. immunoglobulins present on microorganisms or by direct
binding to apoptotic cells; the alternative pathway can be directly activated by inva-
ding microorganisms and the lectin pathway is activated by carbohydrate moieties
present on the surface of invading microbes.  Activation of the complement system
generates opsonic components of complement facilitating phagocytosis of microorga-
nisms and other targets (Aderem and Underhill 1999). Initiation of any of the three
pathways of complement is associated with the activation of the terminal complement
pathway and formation and deposition of C3 and the terminal C5b-9 complement
complex (TCC), also termed the membrane attack complex (MAC).
Deficiencies of complement components of all three pathways are associated with dis-
tinct clinical pathology. Deficiencies of the classical pathway (C1, C4, C2) are associa-
ted with systemic lupus erythematosus (SLE) (Pickering et al., 2000). Deficiency of the
central component of all three pathways of complement activation, C3, is associated
with SLE, pyogenic infections and glomerulonephritis. Patients with deficiencies of
factor D and properdin, components of the alternative pathway, show increased sus-
ceptibility to infections with Neisserial species (Sjoholm 2002). Deficiency of MBL, a
major initiator of the lectin pathway of complement, is frequently found in the gene-
ral population due to point mutations in the coding sequence of the MBL2 gene
(Sumiya et al., 1991); Lipscombe et al., 1992; Madsen et al., 1994). MBL deficiency has
been shown to be associated with bacterial, fungal and viral infections in both children
and adults (Eisen and Minchinton 2003). Apart from infectious diseases, MBL poly-
morphisms have been reported to be associated with systemic diseases such as SLE,
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rheumatoid arthritis and sepsis (Garred et al., 2003; Garred et al., 2000; Davies et al.,
1995). The lectin pathway of complement can also be activated via L-ficolin
(Matsushita et al., 2000) and H-ficolin (Matsushita, et al., 2002), but deficiencies for
these molecules have not been described in the human population. MBL and ficolins
use MASP-2 as the C4-activating enzyme of the lectin pathway. Interestingly, a patient
with MASP-2 deficiency was recently described (Stengaard-Pedersen et al., 2003).
Deficiency of complement components of the common terminal pathway may lead to
defective lysis of microorganisms by the C5b-9 complex, in particular of Neisserial
species (Jack, et al., 2001). Deficiency of regulatory proteins of complement activation
is associated with angioedema in the case of C-1 inhibitor, and with haemolytic urae-
mic syndrome, SLE, glomerulonephritis and bacterial infections for factor I and H defi-
ciency (Sjoholm 2002)
For assessment of the functional activity of the classical and alternative pathways, hae-
molysis of erythrocytes by complement activation either via the classical (CH50) or
alternative pathway (AP50) is used in most laboratories. Functional ELISA based pro-
cedures for the classical and alternative pathways have been developed based on pre-
viously reported methodology (Fredrikson et al., 1993; Roos et al., 2003).  In view of
the clinical relevance of MBL deficiencies, several assays have also been developed to
assess MBL functional activity in human serum. These assays are based on the use of
mannan as a ligand. Of  the two known initiators of the lectin pathway, MBL and fico-
lins, only MBL binds to mannan. Therefore, these assays specifically detect MBL-
dependent activation of the lectin pathway, and we will therefore use the term MBL-
pathway to indicate this specificity.
To evaluate the activity of the MBL/MASP complex, Petersen et al. ( 2001) introduced
an ELISA-based procedure with mannan-coated plates. Because of interference from
classical pathway activation by anti-mannan antibodies, sera are incubated in high
ionic strength buffers. At this tonicity, however, activation of C4 is also inhibited and
Mean activity SD CV (%)
(%)
Classical pathway 85 2.9 3
Alternative pathway 83 5.7 7
MBL pathway 74 3.9 5
One serum sample was tested for classical, alternative and MBL
pathway activity in 40 wells on one occasion.
Table 1. Intra-assay variation for the three pathways of complement activation evaluated with the 
complement kit.
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therefore the activity of the MBL complex is assessed in a second step with exogenou-
sly added purified C4. Therefore, with this assay only the activity of the MBL/MASP
complex can be directly assessed. 
The functional activity of the whole MBL pathway of complement has also been eva-
luated by other procedures. Direct haemolysis of erythrocytes coated with mannan
and indirect haemolysis of chicken erythrocytes, as innocent bystander cells, have
been used (Kuipers et al., 2002; Ikeda et al., 1987). In both assays exogenous MASP and
/or additional complement factors have to be added to the assay system to permit
erythrocyte lysis. Furthermore, both types of assay are difficult to perform on a routi-
ne basis for clinical use and do not exclude participation of the classical pathway in the
assay. In clinical practice, it would be helpful to assess the functional activity of the
whole MBL-pathway, from MBL through to C9, without the use of additional comple-
ment sources. Such ELISA-based procedures have been developed using mannan-
coated plates (Roos et al., 2003; Minchinton et al., 2002) and it has been recently
demonstrated that the contribution of the classical complement pathway in such an
assay can be prevented by addition of an inhibitory antibody directed against C1q
(Roos et al., 2003).
A compromised innate immune system resulting from defective activation of comple-
ment can be caused by genetically determined deficiencies of any of the complement
components. Furthermore, decreased or absent pathway activity may also be caused
by acquired complement deficiencies due to consumption. Here we describe the devel-
opment of a simple ELISA-based format for the evaluation of all three pathways of
complement activation. The assay is now available commercially in kit form. Screening
the sera of patients for complement deficiencies or any other functional defect in the
complement system can now be performed with one simple assay format for the three
pathways analysed in parallel. In the present study we have standardized and valida-
ted these assays for the detection of inherited and acquired complement deficiencies
associated with all three activation pathways. 
Materials and methods
Serum samples
Serum samples were obtained from 120 healthy individuals (registered blood donors),
60 females with a mean age of 44.7 years  (20-69 years) and 60 males with a mean age
of 45.1 years (20-65 years). For each gender 12 donors were selected from each decade
from age 20 to 70. Serum samples obtained were directly aliquoted and stored at -80°C.
The serum samples were tested in three different laboratories in the novel ELISA-
based kit for functional activity of the classical, alternative and MBL pathways, subse-
quently referred to as the complement kit. From six donors plasma samples were also
collected into heparin, EDTA or citrate. These samples were tested in the complement
kit and the results were expressed as a percentage of pathway activity compared to the
pathway activity assessed in serum samples from the same donors. 
Sixty-four serum samples from patients with different well-defined genetically deter
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mined complement deficiencies (Turner and Hamvas 2000;Pickering et al.,
2000;Sjoholm 2002) were collected and tested in six different laboratories within
Europe. Thirty-eight samples were taken from patients with low complement levels
caused by complement consumption. From these patients five were diagnosed with
hypocomplementaemic urticarial vasculitis syndrome (HUVS), seven with hereditary
angio-oedema (HAE), thirteen patients with acquired angioedema (AAE), seven
patients with acute post-streptococcal glomerulonephritis and six sera were from
patients positively tested for the presence of C3 nephritic factor (C3NeF). All samples
taken were directly aliquoted and stored at -80°C. Forty serum samples were selected
from sera sent to one of the laboratories for diagnostic evaluation of complement acti-
vity. These serum samples were from patients with SLE, HUVS or recurrent infections.
These samples were tested for total complement activity in the complement kit.
Mean activity SD CV(%)
(%)
Classical pathway S1 98 4.3 4
S2 92 3.9 4.2
S3 21 1.7 8
Alternative pathway S1 48 5.1 11
S2 89 8.0 9
S3 16 3.1 20
MBL pathway S1 91 3.3 4
S2 37 4.0 11
S3 16 2.3 15
Three different serum samples (S1, S2, S3) were tested in triplicate on 6
occasions for complement activity in the classical, alternative and MBL
pathways.
Table 2. Inter-assay variation for the three pathways of complement activation evaluated with the 
complement kit.
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Figure 1 One hundred and twenty sera from healthy volunteers were tested using the complement kit
in three different laboratories for classical pathway activity (A), alternative pathway activity
(B) and MBL pathway activity (C). The solid lines indicate the mean values of the samples tes-
ted. The mean absorbance values of the serum samples tested in the three laboratories for clas
sical pathway activity (D), alternative pathway (E) and MBL pathway (F) were, 2.079, 1.558
and 1.009, respectively. The MBL pathway activity is plotted against the MBL concentrations
assessed in the same serum samples (F). The solid lines indicate the mean values of the sam
ples tested and the dotted lines indicate the cut off values for normal pathway activity. The dis-
tribution of pathway activity for CP, AP and MBL-P activity is shown in panels G, H and I,
respectively.
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Assessment of pathway activity in normal human serum samples using
the complement kit
The complement kit for assessment of classical, alternative and MBL pathway activity
was developed by the EU consortium and prepared centrally at Wieslab (Sweden). It
is now commercially available (Wielisa COMPL300 Total Complement Functional
Screen kit from Wieslab AB, Lund, Sweden).For the present studies the instructions
provided in the manual were followed. In brief, strips of wells for classical pathway
(CP) evaluation were pre-coated with IgM, strips for alternative pathway (AP) deter-
mination were coated with LPS and MBL pathway (MBL-P) strips were coated with
mannan. Sera were diluted 1/101 for the CP and MBL-P assay and 1/18 for the AP assay
in specific buffers, which ensured that activation of only one of the pathways occurred
(Roos et al., 2003), and were incubated for 1 h at 37°C. After washing the strips, alkali-
ne phosphatase-conjugated anti-human C5b-9 was added before incubation at room
temperature for 30 min. Additional washing was performed, substrate was added and
the wells were incubated for 30 min. Finally, absorbance values were read at 405 nm.
In each assay standard positive and negative control sera provided in the kit as lyop-
hilised material were reconstituted with distilled water. The positive serum was a pool
of 5 sera from healthy individuals and the negative control consisted of sera heat-inac-
tivated at 56°C for 20 min. Complement activity was calculated using the following
formula: Activity = 100 % x (mean A405 (sample) - mean A405 (negative control) /
(mean A405 (standard serum) - mean A405 (negative control). Samples as well as stan-
dard serum and negative control serum were tested in duplicate at a fixed dilution.
Analysis of intra-assay and inter-assay variation
For the assessment of intra-assay variation of the complement kit, one sample was tes-
ted in 40 wells on one occasion for all three pathways. For calculation of the inter-assay
variation three samples were selected and tested on 6 different occasions. The mean
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Figure 2. Serum samples, hepa-
rin plasma, EDTA plasma and
citrate plasma samples were obtai-
ned from six donors for assess-
ment of classical, alternative and
MBL pathway activity. The
pathway activity detected in serum
samples was set at 100% for all
three pathways. The mean
pathway activity and standard
deviations for each condition are
shown.
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values, standard deviation (SD) and the coefficient of variation (CV = SD/mean x 100%)
were calculated for the classical, alternative and MBL pathways.
Haemolytic assays 
For the haemolytic assessment of classical pathway complement activation, sheep red
blood cells (SRBC) were sensitised using rabbit anti-SRBC Abs (Ab-coated erythrocy-
tes (EA)). For a classical pathway test, a total number of 7 x 109 EA diluted in dextrose
gelatin Veronal buffer2+ (0.5x VBS, 0.05% gelatin, 167 mM glucose, 0.15 mM CaCl2, 0.5
mM MgCl2 (DGVB++); volume 50µl) was mixed with serum (final dilution 1/10 in
DGVB++, final volume of 100 µl), for 30 min at 37°C. For the analysis of alternative
pathway activity, a haemolytic assay for the alternative pathway was performed.
Rabbit erythrocytes (7 x 109) suspended in DGVB++ containing 10 mM MgEGTA were
incubated in a 1:1 ratio with human serum, final volume of 100 µl, for 30 min at 37°C.
For both assays, after the addition of 1.5 ml of PBS and centrifugation, haemolysis was
assessed by measuring absorbance at 414 nm. The lytic activity of a sample was expres-
sed in arbitrary units per ml using the following formula: Lytic activity = activity of the
standard serum (U/ml) x (mean A414 (sample) - mean A414 (0 %)) / (mean A414 (stan-
dard serum) - mean A414 (negative control)). In this formula, the A414 (0 %) represents
incubation of EA with buffer only and the A414 (100%) was assessed after the additi-
on of H2O. Normal haemolytic activity was defined as higher than 207 U/ml and hig-
her than 52 U/ml, for the classical pathway test and the alternative pathway test, res-
pectively.
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Figure 3 Functional activity of the classical pathway of 40 serum samples from patients tested in a 
quantitative haemolytic assay plotted against the functional activity assessed with the comple
ment kit (A). For the activity of the alternative pathway the results of a quantitative haemo
lytic assay are plotted against results obtained in the complement kit (B). The dotted lines 
indicate the cut off values for healthy controls.
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Figure 4 Serum samples with well-defined complement deficiencies were tested in the complement kit 
for complement pathway activity in the classical pathway (A), the alternative pathway (B) and
the MBL pathway (C). The group indicated as C5-C9 includes sera deficient in C5 (n = 3), C6
(N = 4), C7 (N = 5), C8 (N = 4) and C9 (N = 2). The group indicated as MBL 0/0 includes 
sera from donors known to be homozygous (C/C, D/D) or compound homozygous (B/D) for 
MBL variant alleles. The group indicated as properdin (P) deficiency included complete pro-
perdin deficiency (N=5), incomplete properdin deficiency (N=2), and properdin dysfunction 
(N=2). The solid lines indicate the mean value of activity in the different assays for healthy 
control samples. The dotted lines indicate the lower cut off values for normal activity for the 
different pathways.
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Measurement of MBL serum concentrations
Assessment of MBL concentrations was performed as described previously (Roos et
al., 2001)
Statistics
The Spearman non-parametric correlation coefficient was used for statistical analysis.
P-values below 0.05 were considered to be statistically significant.
Results
Assessment of complement activity via three pathways in healthy donors
Serum samples from 120 healthy controls were tested for classical pathway activity,
alternative pathway activity and MBL pathway activity in three laboratories as descri-
bed in the Materials and Methods section. The complement activity for each pathway
was expressed as a percentage of the activity of a positive standard serum.  For both
the classical pathway (Fig. 1A) and the alternative pathway (Fig. 1B), complement acti-
vity was detectable in all healthy donors. The inter-individual variation for the alter-
native pathway was somewhat higher than that for the classical pathway. In contrast,
a large inter-individual variation was observed for the activity of the MBL pathway of
complement (Fig. 1C), with undetectable activity in a number of donors. Results for all
three pathways of complement showed a highly significant correlation between the
different laboratories. The correlation coefficients for the classical pathway activity, the
alternative pathway activity and the MBL pathway activity were above 0.71, above
0.67 and above 0.93 (P < 0.001), respectively, for all three pairs of laboratories.
To determine the normal level of activity for the classical and the alternative pathways
of complement activation, the mean percentage of activity of the results assessed in the
three laboratories was calculated (Fig. 1D, E). The lower cutoff value of normal
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Figure 5 Three serum samples with known properdin deficiency (A) and two samples with C1q defi-
ciency (B) had decreased MBL pathway activity. After reconstitution with purified MBL, 
MBL pathway activity was restored. The solid lines indicate the mean activity for MBL
pathway activity as assessed in healthy controls.
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pathway activity for these pathways was defined as the mean percentage of activity
minus two times the standard deviation. For the classical pathway activity the mean
level of activity was 98% and the lower cutoff value of normal pathway activity was
74% (Fig 1D). For the alternative pathway the mean level of activity was 74% and the
lower cutoff value was 39% (Fig 1E). In contrast to the classical and alternative
pathways of complement activation, the MBL pathway activity of the 120 samples
showed a large variation. This variation was strongly dependent on the serum concen-
tration of MBL (Fig. 1F). The threshold level of normal MBL pathway activity was arbi-
trarily set at 10 %, resulting in 28% of the healthy donor sera falling below this thres-
hold (Fig. 1F). More than 90% of these sera had serum MBL concentrations below 300
ng/ml. The distributions of pathway activity, for the 120 sera tested, are shown in
Figures 1G, 1H and 1I for, CP activity, AP activity and MBL-P activity, respectively. 
As shown in Table 1, the intra-assay variation for the three pathways was below 7 %,
whereas the inter-assay variation was below or equal to 20 %.
The results obtained by assessment of plasma samples either collected in heparin,
EDTA or citrate showed reduced pathway activity when compared to the activity
assessed in serum samples from the same patients (Fig 2). 
Correlation with hemolytic assessment of complement activity
Currently in most diagnostic laboratories the functional activity of the classical and the
alternative pathways of complement is assessed by a haemolytic assay, such as the
CH50 for the classical pathway and the AP 50 for the alternative pathway. We selected
40 serum samples showing differing levels of classical pathway and alternative
pathway haemolytic activity, and measured these samples in parallel for classical and
alternative pathway activity using both hemolytic assays and the complement kit. As
indicated in Figure 3, the results obtained in the complement kit showed a good cor-
relation with the results obtained in the quantitative haemolytic assays, both for the
classical pathway (R = 0.89, P < 0.001) and for the alternative pathway (R= 0.84, P<
0.001). For the alternative pathway, the complement kit showed undetectable functio-
nal activity for all serum samples with an alternative pathway haemolytic activity
below the normal value. 
Detection of complement deficiencies with the complement kit
A total of 64 sera with different defined complement deficiencies were assessed for
classical pathway, alternative pathway and MBL pathway activity in the complement
kit (Fig 4 A-C). 
C1q deficient serum samples showed undetectable classical pathway activity, whereas
alternative pathway activity was within the normal range and MBL pathway activity
showed a distribution similar to that seen in healthy donors. Serum samples from well
characterized MBL variant genotypes showed no detectable MBL pathway activity
whereas classical and alternative pathway activities were normal. The MBL pathway
was also deficient in a MASP-2-deficient serum sample. Serum samples deficient in C4
or C2 showed normal alternative pathway activity and undetectable classical and MBL
pathway activity. Alternative pathway activity was decreased in all properdin-defi-
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Figure 6 Serum samples with acquired complement deficiencies and deficiencies of comple-
ment regulatory proteins were tested for complement activity via the classical 
pathway (A), the alternative pathway (B) and the MBL pathway (C) in the com-
plement kit. The solid lines indicate the mean activity for the different pathways as 
assessed in healthy controls. The dotted lines are the cut off values for normal activi-
ty in the different pathways.
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cient sera whereas classical pathway activity was normal and MBL pathway activity
was low in some, but not all of the sera. As expected, because of the central position of
C3 in all three pathways of complement activation, no detectable activity was found in
any of the pathways when C3-deficient sera were analyzed. Similarly, sera deficient in
complement components of the final common pathway (C5b-9) showed, as anticipa-
ted, no activity in any of the three pathways. Taken together, in well-defined comple-
ment-deficient sera, the activity of the involved pathway(s), when assessed in the com-
plement kit were below 10% compared to a standard serum. Among the samples tes-
ted one C9-deficient serum showed slightly more than 10% classical pathway activity
while one serum with incomplete properdin deficiency (properdin deficiency type 2)
showed slightly more than 10% alternative pathway activity. With this possible excep-
tion the three known phenotypic variants of properdin deficiency (Sjoholm 2002) were
all correctly identified with the present ELISA.
MBL deficiency is frequently found in apparently healthy individuals. Therefore, a
combined deficiency of properdin and MBL or C1q and MBL was suspected in sera
showing a decreased activity in more than one of the pathways. By adding purified
MBL to these sera the MBL pathway activity was restored, demonstrating a combined
properdin and MBL deficiency, and combined C1q and MBL deficiency, respectively,
in these sera (Fig 5A and B).
Impaired complement activation can be found in sera from patients with a genetically
determined complement deficiency, as shown above, but complement consumption
can also be an explanation for diminished pathway activity. Therefore, sera were col-
lected from patients with disease or having deficiencies of regulatory proteins that
might cause complement consumption. For this purpose, sera from patients with
HUVS, HAE, AAE, acute post- AGN and sera from patients with C3NeF, were tested
in the complement kit. In addition, serum samples with a genetic factor I or factor H
deficiency were tested. 
Sustained in vivo complement activation as found in the diseases mentioned above
leads to complement deficiencies with decreased activity of one or more of the
pathways of complement activation and this was confirmed using the present kit
(Figure 6). Also deficiencies of regulatory proteins of the alternative pathway of com-
plement causes consumption of complement components including C3 and therefore
decreased pathway activity in all three pathways of activation. 
Discussion
Haemolytic assays to assess the functional activity of the classical and the alternative
pathways of complement activation have been available for some years. However, for
the MBL pathway no comparable assay exists. In order to assess the functional activi-
ty of the MBL pathway an ELISA has been developed in which the activity of the
pathway from MBL through to C9 is assessed in whole serum (Roos et al., 2003). The
degree of activity is assessed as the amount of C5b-9 that is generated and bound in
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ELISA wells coated with mannan. At the same time it is possible to measure classical
and alternative pathway activation using specific reagents and coatings. These three
assays have now been combined in one kit, called the complement kit, and make it
possible to identify defects in any of the three initiating pathways and the terminal
sequence of complement activation in any given serum sample. The standardisation
and validation of this assay revealed it to be a sensitive, specific and simple assay for
the detection of complement deficiencies.
The results obtained in three different laboratories using 120 serum samples from
healthy donors tested for the three pathways correlated well. Because of the limited
variation of complement activity between different sera, particularly in the classical
pathway but also in the alternative pathway, a cut off value for normal pathway acti-
vity could be defined as the mean value of activity minus two times the standard devi-
ation. This approach resulted in 2.5 % of the healthy population falling below the
cutoff value for normal complement activity. The mean value of activity in the alterna-
tive pathway for the 120 sera was 74% of the standard serum alternative pathway acti-
vity. Because of the variation in alternative pathway activity observed in sera from
healthy individuals we conclude that the pool of sera used in the standard had relati-
vely high alternative pathway activity compared to the donor samples tested.
For MBL pathway activity a different method was required to define a cut off value.
Because of the variation in MBL concentration in the normal healthy population,
which is mainly genetically determined (Garred et al., 2003), there is also a large vari-
ation in MBL pathway activity, with a distribution skewed to the left, as confirmed in
the present study. Here an arbitrary minimum level for normal MBL pathway activity
was set at 10% of the standard, which corresponded to MBL concentrations below 300
ng/ml. Using this threshold level, 98 % of the serum samples with reduced MBL
pathway activity had serum MBL concentrations below 300 ng/ml.  Studies on the
association of low MBL serum concentrations and susceptibility to disease such as
infections have shown that patients with serum MBL levels below approximately 300
ng/ml are at risk (Sumiya et al., 1991; Peterslund et al., 2001). Therefore, a cut off value
of 10 % for MBL-P activity is expected to be useful for the detection of MBL deficien-
cy in the complement kit.
An important practical observation was that plasma samples showed decreased
pathway activity compared to serum samples from the same patients. This was espe-
cially true for heparinised plasma used for MBL pathway estimations. Reduced
pathway activity in plasma samples could be explained by dissociation of C1 com-
plexes and MBL-MASP complexes in a calcium-free environment. It takes time to re-
associate these complexes, which makes the complement activation less efficient.
Furthermore, anticoagulants may bind to complement factors, thereby influencing
their activity. This binding is not reversed when diluting the sample. Therefore, only
serum samples should be used to quantify pathway activity in the complement kit.
Complement activity in sera deficient in individual complement components was
below 10% in either one or more pathways.  Combined complement deficiencies in the
MBL pathway and the alternative pathway were demonstrated as well as combined
complement deficiencies in the MBL pathway and classical pathway of complement
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activation. MBL pathway activity was reconstituted when purified MBL was added to
these sera. The results obtained demonstrate the value of the complement kit in the
detection of combined deficiencies in one assay. 
Sera from patients diagnosed with diseases known to cause complement consumption
were also tested with the complement kit. Decreased activity in all three pathways was
demonstrated in most of these sera. Consumption of components of the classical
pathway in patients with hereditary and acquired angioedema is caused by deficient
or non-functional C1-INH (Carugati et al., 2001). C4 and C2 are consumed depending
on the degree of disease activity and, in some patients with AAE, C3 levels are also
low. The present findings were consistent with this. In patients with HUVS, C1q in
serum is depleted in the presence of anti-C1q autoantibodies and the classical pathway
is activated (Wisnieski 2000). In patients with acute post-streptococcal glomerulo-
nephritis the alternative pathway is predominantly activated and the classical
pathway of complement can also be activated via immune complexes (Sjoholm 1979).
The autoantibody C3NeF stabilises the C3 convertase causing enhanced C3 activation
(Daha and van Es 1979). Accordingly, all these conditions are associated with strongly
enhanced complement consumption, which was reflected in our data showing decrea-
sed complement activity in all three pathways. Complement deficiency is also found
in patients with a deficiency in regulatory complement components of the alternative
pathway. Patients with factor H and I deficiency showed decreased activity in all
pathways because of secondary C3 deficiency (Sjoholm 2002). Collectively, the results
demonstrate the value of the complement kit in the detection of acquired complement
deficiencies as well as genetic defects. 
Assays measuring haemolysis of erythrocytes by complement activation either via the
classical or alternative pathway are used on a routine basis to assess the functional acti-
vity of these pathways. To compare the results of complement activation by the classi-
cal and alternative pathways assessed by haemolytic assays or the complement kit,
serum samples were tested in parallel using both methods. A strong correlation was
found between the results obtained by the haemolytic assay compared with those in
the complement kit. Compared to the original definition of AP50 and CH50 different
type of calculation is used to obtain the results in the present complement assays.
Results from the latter assays were originally defined by titration. Therefore, the
results of the complement kit, expressed as percent of activity of a standard serum,
cannot be used as a direct quantitative description of the complement defect. However,
in view of the reproducibility and simplicity of the complement kit, this method
should be regarded as preferable to haemolytic assays for screening of classical and
alternative pathway activity in clinical practice. In patients suspected of having a defi-
ciency of the humoral immune system the complement system should be screened for
deficiencies and immunoglobulin quantity should be assessed. Complement deficien-
cies in any of the three pathways of complement activation can easily be detected in
the new combined assays. We have shown the results of assaying sixty-four sera defi-
cient in one or more of eleven different components of the classical, alternative and
MBL pathways. When, after confirmation in a second independent sample, the scree-
ning assays suggest a complement deficiency, samples should be further analysed in
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specialist laboratories for precise identification of the deficient component. 
In conclusion, a simple assay with a uniform design has been developed by which it is
possible to evaluate functional activity of the three pathways of complement activati-
on in parallel. The assay results are reproducible between different laboratories and
standardization of the assay will permit its use for patient diagnostics. In this respect
we have shown that the assay is able to detect genetic complement deficiencies at all
levels of the complement cascade, as well as acquired complement deficiencies associ-
ated with in vivo complement consumption.
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Abstract
A functionally active complement system is an essential element of an adequate inna-
te immune response. Complement activity depends on the level and function of a large
number of complement molecules. Much attention has been given to the development
of the complement system in the time period after birth and before development of a
fully functional adaptive immune system. Ageing is associated with a progressive
decline in immunity. Not much is known on the effect of ageing on functional activity
of the complement system.
Functional activity of the classical pathway (CP), alternative pathway (AP) and lectin
pathway initiated via MBL (MBL-P) was determined in sera from 120 healthy adults
using a novel ELISA-based method. Age- and gender-dependent differences in activi-
ty of the three complement pathways were studied. In addition, levels of C1q, C2, C4,
factor B and C3 were determined.
Significantly lower AP activity and lower serum concentrations of MBL and C3, but
higher factor B levels, were found in females compared to males. The CP and AP acti-
vity increased during ageing, whereas an age-dependent decrease in MBL-P activity
and MBL serum concentration was found. C2 and factor B levels increased with age in
contrast to a decrease of the C1q and C3 level. CP activity showed a strong correlation
with C2 levels. Furthermore, the results suggest a co-regulation of complement genes
present in the MHC class III region (factor B, C2 and C4), presumably resulting in a
correlation between AP and CP activity, as well as between levels of these molecules
and activity of the CP and AP, respectively. MBL-P activity was only significantly cor-
related with MBL serum concentration. The results from this study do not support an
important role of a functional MBL pathway for longevity. Enhanced CP activity and
AP activity might partially compensate for a decline in immune defence with age. 
Introduction
The complement system, a major component of innate immunity, plays a crucial role
in immune defence against invasive microorganisms in particular during early child-
hood 1;2. Deficiencies of complement components can cause severe and recurrent infec-
tions. Furthermore, complement deficiencies are associated with systemic diseases
such as systemic lupus erythematosus (SLE) 3, haemolytic uremic syndrome (HUS) 4
and kidney diseases 5. 
Ageing is associated with a progressive decline in immunity. The impact of ageing on
adaptive immunity is well accepted 6;7. However, less certainty exists on the effect of
ageing on innate immunity. Impaired function of neutrophils and macrophages as well
as reduced interaction between dendritic cells and T cells, suggest also a decline in
innate immune function 8;9. As a result of impaired immune function, the ability of
elderly to respond to microorganisms is diminished and the number of infectious
diseases is increased. Also the increased incidence of autoimmune diseases might be
related to altered immunity in elderly 10.  
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The complement system is activated via an enzymatic cascade reaction involving three
different activation pathways, namely the classical pathway, the lectin pathway, and
the alternative pathway. Complement activity for each of these pathways depends on
the expression and function of a large number of complement proteins, and genetic
complement deficiencies are described in the great majority of these molecules. These
complement deficiencies are associated with various diseases, in many cases via
enhanced susceptibility to infections. Furthermore, quantitative and qualitative varia-
tion in complement proteins may occur, both due to genetic and environmental fac-
tors.
Deficiency of MBL, one of the three major initiators of the lectin pathway of comple-
ment, is the most common complement deficiency in man 11. A decreased MBL functi-
on is found in about 30% of the population and approximately 10 % is deficient for
MBL. The importance of the MBL-pathway of complement activation has been demon-
strated by the enhanced frequencies of severe infections in childhood. In early child-
hood the immune defence against microorganism is mainly dependent on innate
immunity, i.e. the complement system, because adaptive immunity still has to be deve-
loped. Adults, after being treated with bone marrow-ablative therapy, and therefore
without functional adaptive immunity, with low MBL levels are also more prone to
infections 12. These findings indicate that the MBL pathway is important when adapti-
ve immunity is insufficient. Because of a decline in adaptive immunity in elderly, an
impaired functional activity of the lectin pathway with age could be of influence on the
defence against invasive microorganisms.
On the other hand a recent report showed the backside of MBL in patients with insu-
lin-dependent diabetes mellitus, showing that MBL may be involved in the pathoge-
nesis of micro- and macro-vascular complications 13. Therefore, a decline in functional
activity of the MBL pathway could also be an advantage for longevity. 
With the use of a recently developed combined assay to assess the functional activity
of the classical pathway, the alternative pathway and the MBL-induced lectin pathway
(MBL-P) of complement, the effect of ageing on the complement system and differen-
ces in pathway activity between genders were analysed. Furthermore, quantitative
analysis of key components of the different complement activation pathways was per-
formed in order to explain the variation of complement activity in the human popula-
tion.
Materials and methods
Serum samples
From a population of 120 healthy individuals, registered as blood donors, serum sam-
ples were obtained.  Sixty females with a mean age of 44.7 years  (20-69 years) and 60
males with a mean age of 45.1 years (20-65 years) were included. Serum samples obtai-
ned were directly aliquoted and stored at -80oC.
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Assessment of pathway activity in normal human serum samples using
the complement kit
The complement kit for assessment of classical, alternative and MBL-induced lectin
pathway activity was used according to the manufacturer's instructions. In brief, strips
of wells for classical pathway (CP) evaluation were pre-coated with IgM, strips for
alternative pathway (AP) determination were coated with LPS and MBL-induced lec-
tin pathway (MBL-P) strips were coated with mannan. Sera were diluted 1/101 for the
CP and MBL-P assay and 1/18 for the AP assay in specific buffers to ensure that acti-
vation of only one of the pathways occurred, and were incubated for 1 h at 37oC. After
washing the strips, alkaline phosphatase-conjugated anti-human C5b-9 was added
before incubation at room temperature for 30 min. Additional washing was perfor-
med, substrate was added and the wells were incubated for 30 min. Finally, absorban-
ce values were read at 405 nm. In each assay standard positive and negative control
sera, provided in the kit as lyophilised material and reconstituted with distilled water,
were assessed. The positive standard serum was a pool of 5 sera from healthy indivi-
duals and the negative control consisted of sera heat-inactivated at 56°C for 20 min.
Complement activity was calculated using the following formula: Activity = 100 % x
Table1. Correlation coefficients (*) between the functional activity of three complement pathways 
and serum complement levels in healthy adults.
CP AP MBL-P C1-q MBL C4 C2 fB Age
CP - - - - - - - - 0.41
P<0.0001
AP 0.44
P<0.0001
- - - - - - - 0.29
P=0.0012
MBL-P -0.04
NS
0.009
NS
- - - - - - -0.14
P=0.13
C1q -0.02
NS
-0.012
NS
0.04
NS
- - - - - -0.18
P=0.048
MBL -0.04
NS
-0.04
NS
0.89
P<0.0001
-0.05
NS
- - - - -0.16
P=0.09
C4 0.01
NS
0.38
P<0.0001
0.000
NS
-0.08
NS
-0.07
NS
- - - -0.06
NS
C2 0.51
P<0.0001
0.35
P=0.0001
-0.07
NS
0.02
NS
-0.04
NS
0.18
P=0.07
- - 0.28
P=0.0019
fB 0.30
P=0.001
0.51
P<0.0001
0.03
NS
-0.13
NS
0.05
NS
0.39
P<0.0001
0.42
P<0.0001
- 0.27
P=0.0027
C3 0.02
NS
0.102
NS
0.17
NS
0.29
P=0.002
0.06
NS
0.31
P=0.0012
0.12
NS
0.14
NS
-0.33
P=0.0002
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(mean A405 (sample) - mean A405 (negative control) / (mean A405 (standard serum) -
mean A405 (negative control). Samples as well as standard serum and negative control
serum were tested in duplicate at a fixed dilution. Cut off values were defined as the
mean minus two times the standard deviation of the complement activity of all sam-
ples for each pathway.
Serum complement concentrations
Assessment of MBL concentrations was performed as described previously 14. C1q, C4
and C3 concentrations were assessed using radial immunodiffusion. C2 and factor B
were measured using rocket-immunoelectrophoresis as described by Sjöholm et 
al. 15
Statistics
The Mann Whitney test was used for statistical analysis. Correlation was evaluated
using the Spearman Rank correlation coefficient (R). P-values < 0.05 were considered
to be statistically significant. 
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Figure 1. Complement activity and gender
The classical pathway activity, the alternative pathway activity and the MBL pathway activi-
ty were determined in 120 sera from both healthy men (M) and females (F). The solid lines 
indicate the median values of the samples tested and the dotted lines indicate the cut off
values for normal pathway activity.
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Results
Complement pathway activity in females and males
Classical pathway (CP), alternative pathway (AP) and MBL-induced lectin pathway
(MBL-P) activity in serum samples from 60 males (mean age of 45.1 years, range 20-65
years) and 60 females (mean age of 44.7 years, range 20-69 years) were determined and
analysed for differences between genders. CP activity and MBL-P activity were com-
parable between males and females (Fig 1). However, AP activity was significant lower
for females. The median AP activity for females was 70 % compared with 81 % for
males (P= 0.0003) (Fig 1). Difference in AP activity could possibly be due to differences
in concentration of one of the crucial factors of the AP namely, C3. The median C3 con-
centration for females was 661 ng/ml (range 342-834 ng/ml) compared to 710 ng/ml
(range 555-889 ng/ml) for males (P=0.0035) (Fig. 2A). To study differences in alternati-
ve pathway in more detail also factor B levels were assessed. Surprisingly, factor B
levels were significantly enhanced in females compared to males (P= 0.0003) (Fig 2B).
CP activity was similar between genders, as well as serum levels for C1q, C4 and C2
(Fig. 2C-D). A trend for lower MBL pathway activity, however not significant, in fema-
les compared to males was found (P= 0.13). Accordingly, MBL serum concentrations
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Figure 2. Complement concentration and gender
The concentration of C3 (A), factor (B), C1q (C), C4 (D), C2 (E) and factor B (F) were 
assessed in all samples from males and females. The solid lines indicate the median values of
the samples tested.
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were significantly lower in females. The median MBL concentration for females was
533 ng/ml compared to 843 ng/ml for males (P= 0.03) (Fig.2F). 
Complement pathway activity at different ages
The possible age-related changes in the CP activity, the AP activity, and the MBL-P acti-
vity were analysed (Fig 3 and Table 1). CP activity and AP activity were positively cor-
related with age (Fig 3A and 3B). In contrast, a tendency for an age-related decline in
MBL pathway activity was observed (Fig 3C). Only MBL-P activity of age group 20-29
years was significantly higher than MBL-P activity of age group 60-69 years (P= 0.009). 
Serum concentrations of complement components of the CP as a possible explanation
for the increase in CP activity with age were analyzed (Table 1). Serum concentrations
of C1q and C3 showed an age-related decline. C4 levels remained stable with increa-
sing age. However, C2 levels were positively correlated with age (R= 0.28).
Furthermore, C2 levels strongly correlated with CP activity (R=0.51). 
Consistent with the age-related increase in AP activity, factor B levels increased with
ageing (Table 1). In addition, AP activity was strongly correlated with factor B levels
(R= 0.51). 
In the present analysis the strongest correlation was found between MBL-P activity
and MBL serum levels (R= 0.89) (Table 1). However, MBL concentrations were not cor-
related with age. Only comparison of MBL concentration in the youngest and oldest
twenty individuals reached a significant difference (P= 0.046) (data not shown), consis-
tent with a lower MBL concentration in older people.
Quantitative explanation of variation in complement activity
In order to further explain the variation of complement activity in the present popula-
tion, levels of individual complement components were correlated to the activity of the
three complement pathways (Table 1). CP activity was correlated with AP activity (R=
0.44), C2 levels (R= 0.51), and factor B levels (R= 0.30). The correlation coefficients
between AP activity and levels of factor B, C4 and C2 were R= 0.51, R= 0.35, and R=
0.38, respectively. The closest correlation was found between MBL-P activity and MBL
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Figure 3 Complement activity and ageing
Correlations between age and the classical pathway activity (A), between age and the alterna-
tive pathway activity (C) and between age and the MBL pathway activity were assessed. 
Statistical analysis was performed by Spearman Rank correlation test. 
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concentrations, R= 0.89 (P< 0.0001). Complement levels of C1q and C3 (R= 0.29), C4 and
factor B (R= 0.43), C4 and C3 (R= 0.34), and C2 and factor B levels (R= 0.42) were high-
ly significantly correlated.
Discussion
The present study shows that ageing is associated with an enhanced functional activi-
ty of the classical pathway and the alternative pathway of the complement system.
Although alternative pathway activity is significantly lower in females, the increase in
alternative pathway activity with age is found for both genders. In contrast, ageing
was associated with a decline in MBL pathway activity. 
Much interest has been focused on the MBL pathway of the complement system in
relation to infectious diseases and systemic diseases such as SLE, rheumatoid arthritis
and diabetes mellitus. The importance of a functional MBL pathway in the defence
against invading microorganisms is of major importance in young children before the
development of a fully functional adaptive immunity. MBL concentrations rise swiftly
before birth and are at the highest levels early after birth 16 17 18. However, at older age
the MBL pathway activity might become again important in immune defence against
microorganisms, because of a decline in functional adaptive immunity. In a recent
paper by Ip et al. 19 no age-related difference in the distribution of MBL2 haplotypes
was found, although these authors detected a lower MBL concentration in the elderly.
In the present study a mild decline in MBL pathway activity and MBL concentration
with age was found. In contrast to MBL pathway activity the classical pathway activi-
ty and alternative pathway activity increased with age. The age-associated enhanced
CP activity and AP activity might be a mechanism to compensate for the decline in
adaptive immunity in the elderly for defence against microorganisms. Furthermore,
reduced MBL pathway activity might be compensated by antibody-mediated activati-
on of the classical pathway of complement 20. Because a healthy population was stu-
died, the decline in MBL pathway activity and MBL concentration with age could be
in some way an advantage for longevity. Possibly the harmful role of MBL in the
pathogenesis of atherosclerosis 21 could contribute to longevity for those who have a
reduced MBL function. In the study by Ip et al. 19 the MBL genotype distribution was
similar at different ages. Therefore, the decline in MBL pathway activity and MBL con-
centration with age is possibly dependent on environmental differences.
In contrast to the MBL-P, our study showed an age-related increase in activity of both
the CP and AP. In earlier studies on classical pathway activity in healthy subjects aged
between 20 and 79 years old, increased CH50 activity during ageing was observed,
associated with increased levels of individual components of the classical pathway 22.
In the present study C4 concentration remained constant and to our surprise a decline
in C1q and C3 concentrations was found. However, C2 levels, the rate-limiting factor
of the CP 23, increased with age. In line with this, C2 levels were strongly correlated
with CP activity. Furthermore, levels of factor B increased with age, and factor B levels
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also strongly correlated with AP activity. Interestingly also a correlation was found
between C4 and factor B and between C2 and factor B concentration. Earlier reports on
haemolytic activity of complement and C3, C4 and factor B levels in healthy children
also showed correlations between C4 and Factor B 24. This could be partially explained
by the localisation of the genes encoding for C4, C2 and factor B, close to each other in
the MHC class lll region on chromosome 6, which may be subjected to similar regula-
tory mechanisms.  The association between AP activity and the classical pathway com-
ponents C4 and C2, as well as the association between CP activity and factor B are pos-
sibly observed as a result of such a co-regulation of genes.
The present study shows a clear correlation between CP activity and AP activity (R=
0.44, P< 0.0001). The correlation between the activities of both pathways could possi-
bly be explained by a co-regulation of expression of C2, factor B and C4, as explained
above, of which the former two determine activity of the CP and the AP, respectively.
Furthermore, an additional role of components of the terminal pathway, which are
shared by all three complement activation pathways, can not be excluded. The compo-
nents of the terminal pathway (C5, C6, C7, C8 and C9) were not quantified in the pre-
sent study. 
Sex hormones are well known to have influence on innate and adaptive immunity 25.
Hormonal differences between genders might result in a higher incidence of autoim-
mune diseases in females. Although the important role of complement in autoimmu-
ne diseases is well established, little is known about differences in functional activity
and serum levels of complement between genders. In the present study a significant-
ly lower AP pathway activity was found in females compared to males, whereas a ten-
dency for lower MBL-P activity was found. Similar results are reported in earlier stu-
dies showing a reduced innate immune response in females assessed by reduced TNF
production by blood cells after stimulation with LPS 26. In the pathogenesis of autoim-
mune diseases, such as SLE, impaired clearance of apoptotic material is proposed to
play an important role. Complement has been shown to participate in the clearance of
apoptotic material. Therefore, reduced complement function in females might contri-
bute to the increased incidence of SLE in females. 
In conclusion:
Although an age-associated decline in innate immunity has been suggested this could
not be confirmed for the functional activity of the complement system. Classical
pathway activity and alternative pathway activity significantly increased with age.
However, an age-associated decline in MBL-pathway activity was found. These data
suggest that MBL is not necessarily important for longevity. Lower functional comple-
ment activity might contribute to increased frequency of autoimmune diseases in
females. 
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Loss of immunologic tolerance is the main characteristic in the pathogenesis of SLE.
As a consequence of the loss of tolerance, autoantibodies directed against a wide varie-
ty of antigens are present in serum from patients with SLE. These antibodies, even pre-
sent before clinical onset of the disease, are thought to be involved in the initiation
phase of SLE 1.  The important protective role of the complement system in the devel-
opment of SLE is best illustrated by C1q knockout mice, who develop a lupus nephri-
tis-like disease 2. In man, deficiencies in early components of the classical pathway of
the complement system are associated with the development of SLE 3. Complement
deficiency has been suggested to be involved in the loss of tolerance and generation of
autoantibodies due to ineffective clearance of apoptotic material. Indeed, a role for
complement components of the classical pathway in the clearance of apoptotic mate-
rial has been demonstrated, both in vitro and in vivo 4;6. Patients with SLE have increa-
sed numbers of circulating apoptotic cells. Ineffective clearance but also enhanced
generation of apoptotic material in patients with SLE could explain the increased cir-
culating amount of apoptotic cells. To demonstrate that apoptotic cells are able to
generate an autoimmune response, mice have been injected with thymocytes rendered
apoptotic by UV-radiation 7. When large numbers of apoptotic cells are injected in
healthy mice they indeed develop an autoimmune response. With lower numbers of
apoptotic cells, an adjuvant is required to induce autoimmunity such as Freund's
incomplete adjuvant or dendritic cells 8. Results from these studies suggest that physi-
ological quantities of apoptotic material, as found in every individual, are not suffi-
cient to induce autoimmunity, but increased amounts are required. Furthermore, the
requirement of a second hit supports the hypothesis that SLE can be induced by infec-
tions, establishing the necessary environment for pathophysiological levels of apopto-
tic material to induce autoimmunity.
As mentioned above, inefficient clearance of apoptotic material could enhance the
level of circulating apoptotic material. The importance of complement in the clearan-
ce of apoptotic cells is well illustrated by the increased amount of apoptotic cells found
in C1q-deficient mice 2. Furthermore, C1q-deficient patients are at high risk to develop
SLE. Also MBL participates in the recognition of apoptotic cells by phagocytes and
patients with MBL-deficiency have an increased risk to develop SLE 4;6;9. Abnormal
clearance of apoptotic cells in MBL-deficiency has thus far not been reported in human
or animal studies. To investigate whether ineffi an MBL-deficiency, can enhance auto-
reactivity, the presence of autoantibodies was assessed in SLE patients with or without
an MBL-deficiency. In the present thesis autoantibodies against C1q and cardiolipin
were more frequently found in patients with MBL variant alleles, low MBL concentra-
tion or low MBL functional activity. Furthermore, anti-MBL autoantibodies were only
found in patients with high serum MBL levels. This could indicate that only functio-
nally active MBL can bind to apoptotic cells and be presented as autoantigen. A higher
frequency of anti-MBL autoantibodies has been shown in patients with SLE. However,
a pathogenic role for these antibodies has to be demonstrated. 
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Taking these results together, MBL might play an important protective role in the onset
of SLE by clearing apoptotic material and thereby preventing the formation of autoan-
tibodies against molecules associated with apoptotic cells. However, when apoptotic
material is insufficiently cleared because of other deficiencies than an MBL defect,
MBL itself might be presented as autoantigen.  
A functionally active MBL pathway is important for host defence against invading
microorganisms. Activation of the complement cascade via MBL-binding to microor-
gamisms result in the formation of the membrane attack complex and causes cell lysis.
Activation of the MBL pathway on self-structures however might cause tissue dama-
ge, as is also true for the other pathways of complement activation. Damage to renal
tissue in lupus nephritis is associated with deposition of complement components of
the classical pathway and consumption of serum complement components. Data pre-
sented in the present thesis suggest a similar down side for MBL, as previously has
been demonstrated for C1q. Renal MBL deposition and lower MBL serum levels in a
mouse model for lupus nephritis point to activation of the MBL pathway in renal tis-
sue. Also in human renal biopsies deposition of MBL has been demonstrated (Roos
and Pia Restaldi unpublished data). Therefore, a functional MBL pathway could be a
disadvantage during the effector phase of the disease. Not only in SLE but also in dia-
betes type 1 and in ischaemia/reperfusion injury a functionally active MBL pathway
might cause more damage than being protective 10;11. With these findings it is difficult
to predict whether therapy by either restoration of MBL activity or inhibition of MBL
activity with antibodies or proteins might be helpful in patients with SLE. Probably,
young children with severe recurrent infections, because of MBL deficiency, benefit
from MBL reconstitution therapy. But in patients with SLE this would be highly depen-
dent on the stage of the disease. Infusion of MBL to enhance clearance of apoptotic
cells would potentially be beneficial before generation of autoantibodies has started.
However, no clinical markers are known to indicate whether apoptotic material is inef-
ficiently cleared before the presence of autoantibodies. Infusion of MBL after onset of
the disease might cause MBL deposits in tissue and activation of the complement sys-
tem resulting in enhanced inflammation. Furthermore, binding of infused MBL to
apoptotic material in patients with SLE who are not able to clear apoptotic material
sufficiently, might induce production of anti-MBL autoantibodies.
The MBL pathway of complement activation plays a dual role in the initiating and effector
phase of SLE. A functional MBL pathway is a disadvantage in SLE when MBL deposits in renal
tissue and activates  the complement system, resulting in renal damage. Furthermore, antibo-
dies against MBL are generated in patients with SLE. On the other hand a non-functional MBL
pathway is associated with a higher risk to develop SLE, possibly involving autoantibody pro-
duction as a consequence of inefficient clearance of apoptotic material. 
Deficiency of MBL, a major initiator of the lectin pathway of complement, is frequent-
ly found in the general population due to point mutations in the coding sequence of
the MBL2 gene. Genetic studies have shown that patients with MBL variant alleles are
at risk for infectious diseases and for systemic diseases such as SLE and rheumatoid
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arthritis 9;12;13. In most of the studies a similar association was observed between low
MBL serum concentrations and susceptibility to these diseases. The explanation given
for the association between MBL and infectious diseases is that only functionally acti-
ve MBL can bind to microorganisms efficiently and activate the complement system.
Complement activation on the surface of microorganisms via the classical pathway, the
alternative pathway or the lectin pathway result in opsonisation and formation of the
membrane attack complex.  Therefore, assessment of functional activity of the comple-
ment system is required in patients with recurrent infections. Also in other diseases,
when a deficiency in innate immunity is suggested, or in diseases known to be associ-
ated with complement deficiency or complement consumption, information about the
functional activity of the complement pathways is essential. 
The functional activity of the classical and the alternative pathway can be measured by
assessed of formation of the membrane attack complex on the surface of (sensitized)
erythrocytes. The amount of cell lysis is used as measure of functional activity of the
pathway. Such an assay is not available for the MBL pathway. MBL/MASP complex
activity can be directly assessed but only informs about the binding ability of MBL to
a ligand and the complement-activating capacity of the proteases associated with the
MBL molecule 14. A new complement assay developed to assess the functional activity
of the total MBL pathway is described in the present thesis. The method is ELISA-
based and formation of the terminal complex is assessed in parallel for the classical,
alternative and MBL pathway. The advantage of this assay is the easy and reproduci-
ble way to detect deficiencies of complement components in any of the three
pathways. Furthermore, reduced functional activity of the pathways in diseases with
complement consumption can be detected. With the results of the functional activity
of the three different pathways it is simply to determine, which of the complement
component(s) in a given serum is (are) deficient. In table 1 the possible test results are
shown in relation to certain complement deficiencies. To determine a single comple-
Complement
deficiency
Test result ELISA Frequently associated diseases
CP1 AP2 MBLP3
C1q, C1r, C1s, = = SLE
MBL, MASP-2 = = Recurrent infections 
C4, C2 = Recurrent infections 
Factor B, D, P = = Neisserial infections 
C3 SLE, pyogenic infections, glomerulonephritis
C5, C6, C7, C8, C9 Neisserial infections 
C1-inhibitor (C1Inh) Angioedema
Factor H en I SLE, infections, glomerulonephritis, HUS
1
Classical pathway (CP),
2
Alternative pathway (AP),
3
MBL induced lectin pathway (MBLP)
Table 1. Possible test results of the novel complement assay
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ment component deficiency responsible for the reduced pathway activity, further ana-
lysis is required. 
Age-related changes in innate and adaptive immunity in the elderly are a topic of
much interest. Research for changes in innate immunity has been focused on the cel-
lular compartment 15. With the use of the new complement assay it is now possible to
study the age-related changes in functional activity of the complement system. In the
present thesis the functional activity of the MBL pathway was reduced in elderly.
Given that the samples were taken from healthy individuals, a reduced functional acti-
vity of the MBL pathway is not required for good health in elderly. Possibly antibody-
mediated activation of the classical pathway of complement possibly compensate for
reduced MBL pathway activity 16.  In a previously reported study in large Danish
population it was shown that MBL deficiency was not a major risk factor for morbidi-
ty or death 17. Taken together, it can be concluded that the MBL pathway is not impor-
tant for longevity in relation to infectious diseases in the Caucasian population.
Regulation of innate and adaptive immunity is different between genders. Women are
reported to mount a more vigorous immune response compared to men 18. The role of
sex hormones on regulation of immunity is best illustrated with the changes in activi-
ty of autoimmune disease during pregnancy. Furthermore, the incidence of autoim-
mune diseases is higher in women than in men. The results in the present thesis show
a lower MBL pathway activity in the female population. This result, in perspective of
the role of MBL in the development of SLE as presented in the thesis, might possibly
suggest that lower MBL pathway activity in females partially explains the higher inci-
dence of SLE in females. Furthermore, in earlier studies a role for the alternative
pathway and MBL pathway in the pathogenesis of IgA nephropathy has been sugge-
sted 19;21. Lower AP activity and MBL-P in females, demonstrated in the present thesis,
might contribute to the lower incidence of IgA nephropathy in females compared to
males. 
An age-related enhanced complement pathway activity for the CP and the AP might protect the
elderly against infections when adaptive immunity declines. In females lower functional com-
plement activity might predispose to (auto)immune mediated diseases.
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Mannose-binding lectin, one of the initiating components of most recently described
pathway of complement activation, the lectin pathway, has been suggested to play a
protective role in patients with SLE. MBL deficiency is a risk factor for acquiring SLE.
Furthermore, patients with SLE who are homozygous carriers of MBL variant alleles
have an increased risk for complications such as arterial thrombosis, infections, and
renal involvement. Autoantibodies, generated in patients with SLE, are thought to
play an important role in most of the complications and tissue damage. 
The principal idea of the generation of autoantibodies in patients with SLE is a defec-
tive waste disposal mechanism. An important role in clearance of apoptotic material
for complement components i.e., C1q but also MBL, has been demonstrated.
However, the role of C1q in SLE has been described as a two-edged sword, necessary
for clearance of immune complexes and apoptotic material but damaging when bin-
ding to deposited immune complexes in tissue. In parallel with the findings for C1q a
potential dual role for MBL in patients with SLE was investigated. 
Chapter 2. Does MBL play a role in tissue damage in lupus nephritis?
Activation of the complement system is one of the major causes of organ damage in
SLE patients with active disease. In renal tissue from patients with lupus nephritis the
characteristic finding of a full house immunofluorescence with the presence of C1q
and C3 is used as a diagnostic criterion. Also a relation between organ damage and
decreased serum levels of components of the classical and alternative pathway has
been reported. MBL deposition in renal tissue from patients with active lupus nephri-
tis has been demonstrated but no details about a pathogenic role for MBL has been
reported. To study the role of the MBL pathway in lupus nephritis MRL +/+ mice and
MRL-lpr mice were used. These mice spontaneously develop an autoimmune disease
resembling SLE. However, in MRL-lpr mice the disease is more aggressive and signs
of organ damage occur at earlier age. In renal tissue from these mice deposition was
observed of C1q, MBL-A, MBL-C and C3. These depositions were more pronounced
with increasing age. Furthermore, serum levels of MBL-A, MBL-C, C1q and C3 decrea-
sed with age of these mice.  Also a reduced classical pathway activity was found
during ageing. Alternative pathway and MBL pathway activity remained constant.
Elevated BUN levels and proteinuria demonstrated the development of renal damage
in these mice. These results support the hypothesis that the MBL pathway is involved
in tissue damage in lupus nephritis.
Chapter 3. Do patients with SLE have auto-reactivity against MBL?
The presence of a wide variety of autoantibodies is a characteristic finding in SLE.
Autoantibodies against nuclear proteins, such as anti-nuclear and anti-double stran-
ded DNA antibodies, are used as diagnostic markers in SLE. In earlier studies anti-C1q
antibodies in sera from patients with SLE are found in almost all patients with severe
renal involvement. Recently, anti-C1q antibodies are reported to be pathogenic to the
kidney in the context of C1q-deposition on IgG in glomerular immune complex disea-
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se. MBL deposition has been demonstrated in renal tissue in lupus nephritis. A similar
possible role for anti-MBL antibodies as the pathogenic role of anti-C1q antibodies in
SLE could be hypothesized. Anti-MBL autoantibodies were demonstrated in sera from
patients with SLE. The antigenic specificity of these autoantibodies was demonstrated.
Also anti-C1q antibodies were found in sera from these patients, in association with
renal involvement and disease activity. No association between clinical characteristics
or disease activity and the presence of anti-MBL antibodies could be demonstrated.
The presence of anti-MBL autoantibodies was associated with reduced MBL/MASP
complex activity. Therefore, anti-MBL autoantibodies are possibly able to interfere
with the functional activity of MBL, which could thereby lead to impaired MBL-
mediated clearance of apoptotic material and impaired protection against microorga-
nisms. 
Chapter 4. Does MBL deficiency play a role in the generation of autoantibodies in
SLE?
An impaired "waste-disposal" mechanism is one of the current theories on the patho-
physiology of SLE. The complement system plays an important role in clearance of
apoptotic material. Impaired clearance of apoptotic material might lead to presentati-
on of proteins from this apoptotic material, by antigen presenting cells, as autoanti-
gens and subsequently, to generation of autoantibodies. Autoantibodies are already
found in very early stages of SLE, even before clinical onset. These autoantibodies are
mostly directed against antigens present on apoptotic material. Since MBL has been
postulated to play a role in the clearance of apoptotic material, the presence of autoan-
tibodies in SLE patients in relation to MBL gene polymorphisms and MBL functional
activity was studied.
The results from this study indicated that expression of MBL variant alleles in SLE
patients was not only associated with reduced MBL concentrations but also with
impaired MBL complex activity and impaired MBL pathway activity. Furthermore, it
is demonstrated that MBL gene polymorphisms, low MBL concentration and impaired
functional activity of the MBL pathway are significantly associated with the presence
of anti-cardiolipin and anti-C1q antibodies in patients diagnosed with SLE. In additi-
on, SLE disease activity was higher in patients with lower MBL-pathway activity. 
This study supports the hypothesis that MBL deficiency or dysfunction might play a
role in the onset and severity of SLE, possibly caused by insufficient clearance of apop-
totic debris, leading to increased production of autoantibodies against persisting self
antigens.
Conclusion
In MBL deficient patients with SLE enhanced autoantibody production has been
demonstrated, which might indicate that the MBL pathway of complement activation
plays a protective role in SLE by clearance of apoptotic material.  However, activation
of the MBL pathway might aggravate organ damage in SLE.  In addition, autoantibo-
dies against MBL, generated in patients with SLE might interfere with the functional
activity of MBL. 
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Chapter 5. Assessment of mannose-binding lectin pathway activity.
A compromised innate immune system resulting from defective activation of comple-
ment can be caused by genetically determined deficiencies of any of the complement
components. Furthermore, decreased or undetectable pathway activity may also be
caused by acquired complement deficiencies due to consumption.
A functional innate immune system is essential for primary defence against invading
microorganisms and the complement system plays a major role in such immunity.
Deficiencies in one of the components of the complement system can cause severe and
recurrent infections, systemic diseases such as systemic lupus erythematosus (SLE)
and renal disease. Haemolytic assays to assess the functional activity of the classical
and the alternative pathways of complement activation have been available for many
years. However, for the MBL pathway no comparable assay exists. A simple ELISA-
based format for the evaluation of three pathways of complement activation is descri-
bed. The assays are based on specific coatings for each pathway in combination with
specific buffer systems. The degree of activity is assessed on the basis of the amount of
C5b-9 that is generated and bound in ELISA wells. These assays are standardised and
cut off values to detect complement deficiencies at the different levels of the comple-
ment system are defined. Furthermore, the assays are validated for the detection of
genetic and acquired complement deficiencies associated with all three activation
pathways. The results demonstrate the value of these ELISA-based procedures for the
functional assessment of complement deficiencies in clinical practice. Screening the
sera of patients for genetic complement deficiencies or any other functional defect in
the complement system can now be performed with one simple assay format for the
three pathways analysed in parallel. 
Chapter 6. Age-related changes in functional activity of complement and differen-
ces between genders
Much attention has been focused on changes in complement activity in early child-
hood. Defence against microorganisms in the time period after immune protection by
maternal antibodies, are based on an adequate innate immune response, followed by
the development of protective adaptive immunity. However, in the elderly a decline in
adaptive immunity has been demonstrated. A functionally active innate immune sys-
tem is important for immune protection against microorganisms. However, the func-
tional activity of the cellular compartment of the innate immune system also declines
with age. Age-related changes in complement activity are scarcely investigated. The
results from the present study show a significantly increase in classical pathway (CP)
activity and alternative pathway (AP) activity with age. The increase in these
pathways might be a tool to compensate for the decline in other immune mechanisms
with age. However, an age-dependent decrease in MBL pathway activity was obser-
ved. A possible advantage of lower MBL pathway activity could be the reduced harm-
ful effect of MBL on (ischaemic) vascular injury. The increase in CP and AP activity
could be explained by enhanced concentrations of, C2 and factor B, respectively, with
age. Lower MBL pathway activity was caused by lower MBL serum concentrations
with age. Between genders a significantly lower AP activity was found in females.
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Lower C3 levels in females could possibly explain the difference in alternative
pathway activity between genders. In the present study we show an enhanced innate
immunity with age in relation to CP activity and AP activity. MBL pathway activity
declined with age. Gender-associated differences in pathway activity and serum con-
centrations were also observed. Differences in functional activity of the complement
pathways between genders may have consequences for the incidence of (auto) immu-
ne diseases. 
Conclusion
Enhanced functional activity of the CP and AP with ageing is demonstrated and might
be important for protection against infectious diseases in elderly when adaptive
immunity declines. The difference in complement activity between genders is sugge-
sted to play a role in the incidence of development of (auto) immune diseases.
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De integriteit van het menselijk lichaam wordt dagelijks op de proef gesteld door het
ons omringend milieu. Het aangeboren en verworven afweersysteem moet het
lichaam beschermen tegen invasieve pathogene micro-organismen. Vooral bij het her-
kennen en opruimen van deze micro-organismen speelt het aangeboren afweersys-
teem een belangrijke rol. Behalve inzake dit lichaamsvreemde materiaal is het aange-
boren afweersysteem ook van essentieel belang voor het opruimen van lichaamseigen
materiaal dat, door al dan niet geprogrammeerde (apoptotische) celdood, zijn functie
heeft verloren.
Eén van de belangrijkste onderdelen van het aangeboren afweersysteem is het comple-
mentsysteem. Het speelt in het opruimen van micro-organismen en lichaamseigen
materiaal een cruciale rol. Deficiënties in het complementsysteem kunnen leiden tot
recidiverende infecties, systeemziekten zoals 'systemische lupus erythematosus' (SLE)
en nierziekten.
Het complementsysteem bestaat uit meerdere routes die op verschillende manieren in
werking gesteld kunnen worden. Welke route geactiveerd wordt, hangt af van de
structuur die door één van de complementfactoren wordt herkend. De klassieke route
wordt geactiveerd door C1q nadat het aan o.a. antistoffen en dode cellen gebonden is. 
De alternatieve route wordt na het binden van spontaan geactiveerd C3 aan bijvoor-
beeld celwandbestanddelen van bacteriën in werking gesteld. De lectine route wordt
geactiveerd door het binden van bijvoorbeeld mannose-bindend lectine (MBL) aan
verschillende suikers. Wanneer één van deze routes geactiveerd wordt zal, na een cas-
cade van  enzymatisch geactiveerde complementcomponenten, een eiwitcomplex (het
"membrane attack complex") gevormd worden. Dit eiwitcomplex is onder andere in
staat micro-organismen te doden. Tijdens de activatie van complementfactoren ont-
staan er fragmenten van complementcomponenten die er voor zorgen dat ontstekings-
cellen aangetrokken worden naar de plaats van complementactivatie. Dit proces zal
ertoe leiden dat het micro-organisme gedood en vervolgens opgeruimd wordt door
cellen van het afweersysteem. Wordt het complementsysteem echter geactiveerd op
lichaamseigen cellen en/of weefsel, en volgt hetzelfde proces als hierboven beschre-
ven, dan zal dit leiden tot schade aan het gezonde weefsel. Zo kan het complementsy-
steem dus een beschermende functie hebben, maar ook de integriteit van de organen
doorbreken.
Het functioneren van het complementsysteem als een aan twee kanten snijdend
zwaard, kan goed geïllustreerd worden aan de hand van complementdeficiënties en
het gevolg daarvan. Patiënten met een deficiëntie voor C1q, de eerste factor van de
klassieke route, presenteren zich bijna allemaal met de ziekte systemische lupus ery-
thematosus (SLE). Echter, bij patiënten met SLE zónder een C1q deficiëntie zal de scha-
de, die bijvoorbeeld ontstaat in de nieren van deze patiënten, voor een groot deel ver-
oorzaakt worden door activatie van de klassieke route van het complementsysteem.
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Om deze twee facetten te begrijpen moeten we rekening houden met het feit dat bij het
ontstaan en het beloop van een ziekte (in dit geval SLE) niet dezelfde mechanismen
een rol hoeven te spelen. C1q blijkt een belangrijke rol te spelen in het opruimen van
immuuncomplexen. Wanneer immuuncomplexen efficient worden opgeruimd kun-
nen zij niet in de nier neerslaan en daarom geen aanleiding kunnen geven tot een ont-
stekingsreactie. Slaan immuuncomplexen, ondanks de aanwezigheid van C1q, wel
neer in de nier, dan kan, door het binden van C1q aan deze immuuncomplexen, het
complementsysteem lokaal geactiveerd worden en er schade aan de nier ontstaan.
MBL, de complementfactor die na het binden aan een suiker de lectine route activeert,
heeft structurele en functionele eigenschappen die lijken op die van C1q. Of MBL ook
een dubbele rol, zoals C1q, kan vervullen in het ontstaan en beloop van SLE is echter
niet duidelijk. 
MBL lijkt een beschermende rol te spelen bij het ontstaan van SLE. Uit studies is geble-
ken dat het hebben van een MBL-deficiëntie een risicofactor is voor het ontwikkelen
van SLE. Ook hebben patiënten met SLE én een MBL-deficiëntie een toegenomen risi-
co op het krijgen van complicaties zoals trombose en infecties. Tevens zou MBL een rol
kunnen spelen in de ontwikkeling van autoantistoffen bij patiënten met SLE. Eén van
de huidige theorieën omtrent de ontwikkeling van autoantistoffen in SLE duidt op een
niet goed functionerend systeem voor de verwerking van apoptotisch materiaal. Zoals
al eerder genoemd lijkt het complementsysteem, met name de complementcomponen-
ten C1q en MBL, een belangrijke rol bij het opruimen van dit celafval te spelen. Zo zou
het kunnen dat, wanneer iemand een MBL-deficiëntie heeft, het apoptotisch materiaal
niet goed geklaard wordt hetgeen kan leiden tot de productie van autoantistoffen. 
Of MBL ook een schadelijke rol speelt bij het ontstaan of in het beloop van SLE is
onduidelijk. Aanwijzingen voor een mogelijke rol van MBL in het veroorzaken van
schade, zijn de aanwezigheid van zowel C1q als MBL in de nierbiopten van patiënten
met SLE.
Of MBL inderdaad functioneert als een aan twee kanten snijdend zwaard, is in de hui-
dige studie verder onderzocht.
Hoofdstuk 2. Speelt MBL een rol bij het ontstaan van weefselschade in nierontste-
king bij SLE patiënten?
In het mechanisme dat leidt tot weefsel- en orgaanschade bij patiënten met SLE gedu-
rende een actieve periode van hun ziekte, speelt de activatie van het complementsy-
steem een belangrijke rol. De aanwezigheid van zowel antistoffen als complement bij
microscopisch onderzoek van een nierbiopt wordt gebruikt als één van de criteria bij
het stellen van de diagnose SLE. Eveneens is er een relatie aangetoond tussen orgaan-
schade en verlaagde serumwaarden van componenten van de klassieke en alternatie-
ve route. 
MBL-neerslag in nierbiopten van SLE patiënten met actieve nierziekte ("lupus nefri-
tis") is aangetoond, maar verder zijn er geen gegevens bekend voor een mogelijk
pathogene rol van MBL in de nier. Om de rol van de MBL-route in "lupus nefritis" te
bestuderen hebben wij gebruik gemaakt van MRL-lpr and MRL +/+ muizen. Beide
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muizen ontwikkelen spontaan een auto-immuunziekte die lijkt op SLE. MRL-lpr mui-
zen ontwikkelen echter een veel sneller en ernstiger verlopende ziekte dan MRL +/+
muizen. In nierweefsel van deze muizen werd een neerslag gevonden van C1q, MBL-
A, MBL-C en C3. De mate van neerslag van deze componenten nam toe met de leef-
tijd. De serumconcentratie van C1q, C3, MBL-A en MBL-C nam in alle muizen af gedu-
rende het ouder worden. Binnen de verschillende routes nam met het toenemen van
de leeftijd alleen de routeactiviteit van de klassieke route af. De activiteit van de alter-
natieve en MBL-route bleef gelijk. Dat de muizen daadwerkelijk een nierziekte ontwik-
kelen werd vastgesteld aan de hand van een toegenomen serum ureum concentratie
en sterk verhoogde albumine excretie in de urine bij hogere leeftijd. Met deze bevin-
ding werd de betrokkenheid van de MBL route in het ontstaan van weefselschade bij
"lupus nefritis" waarschijnlijk geacht.
Hoofdstuk 3.  Hebben patiënten met SLE autoreactiviteit tegen MBL?
De aanwezigheid van autoantistoffen gericht tegen veel verschillende antigenen is een
karakteristieke bevinding bij SLE. De aanwezigheid van autoantistoffen in het serum
van patiënten met SLE gericht tegen kerneiwitten en DNA wordt gebruikt als criteri-
um om de diagnose SLE te stellen. Anti-C1q antistoffen worden bijna altijd aange-
toond in het serum van patiënten met ernstige lupus nefritis. Anti-C1q antistoffen kun-
nen een pathogene rol spelen in de nier wanneer C1q gebonden is aan IgG deposities
in de glomeruli. Omdat ook de aanwezigheid van MBL in de nier van patiënten met
lupus nefritis is gevonden, zou een vergelijkbaar mechanisme, als recent aangetoond
voor anti-C1q antistoffen, voor anti-MBL antistoffen kunnen gelden. 
Inderdaad vonden wij in patiënten met SLE naast anti-C1q antistoffen ook anti-MBL
antistoffen in het serum. De antigeen-specifieke binding van anti-MBL antistoffen
voor MBL werd vastgesteld. 
Zoals al eerder beschreven is, werd ook in de huidige studie een verhoogde spiegel
van anti-C1q antistoffen bij patiënten met actieve ziekte gevonden. Voor anti-MBL
antistoffen werd geen verhoogde spiegel aangetoond. De associatie tussen anti-C1q
antistoffen en lupus nefritis werd in deze studie bevestigd. Voor de aanwezigheid van
anti-MBL antistoffen werd geen associatie gevonden met de betrokkenheid van een
specifiek orgaan.
Het is bekend dat SLE patiënten met een MBL-deficiëntie vaker infectieuze complica-
ties doormaken. Mogelijk veroorzaakt een niet goed functionerende MBL route een
inadequate lysis van bacteriën.  Helaas waren er geen klinische gegevens beschikbaar
omtrent infectieuze complicaties. Wel werd er een verminderde activatie van C4 door
het MBL molecuul vastgesteld in aanwezigheid van anti-MBL antistoffen. Anti-MBL
antistoffen zouden dus de functionele activiteit van de MBL route kunnen verstoren
wat zou kunnen leiden tot inefficiënt opruimen van dode cellen en verminderde
bescherming tegen bacteriën.
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Hoofdstuk 4. Leidt MBL deficiëntie tot toename van productie van autoantistoffen
in SLE?
Eén van de huidige concepten over de pathofysiologie van SLE, beschrijft een niet
goed functionerend mechanisme voor het verwerken van apoptotisch materiaal, het
"waste disposal" mechanisme. In het opruimen van apoptotisch materiaal speelt het
complementsysteem een belangrijke rol. Wanneer het apoptotisch materiaal niet goed
geklaard wordt, ontwikkelen patiënten met SLE autoantistoffen gericht tegen antige-
nen die zich aan het oppervlak van dit apoptotisch materiaal bevinden. Deze autoan-
tistoffen kunnen al in het serum aangetroffen worden voordat het volledige klinische
beeld van SLE zich ontwikkeld heeft. Omdat van MBL is aangetoond dat het een rol
speelt bij het opruimen van apoptotisch materiaal, werd de aanwezigheid van autoan-
tistoffen in SLE-patiënten met een MBL-dysfunctie onderzocht.
In deze studie is aangetoond dat de aanwezigheid van MBL genpolymorfismen niet
alleen geassocieerd is met een verlaagde MBL-concentratie maar ook met verminder-
de MBL-functie. Tevens werd gevonden dat MBL-gen polymorfismen, MBL-concen-
tratie en MBL-dysfunctie geassocieerd is met de aanwezigheid van autoantistoffen
tegen componeneten vn dode cellen. Daarnaast werd er gevonden dat de ernst van de
ziekteactiviteit geassocieerd is met  verminderde MBL route activiteit. De resultaten
van deze studie ondersteunen dan ook de hypothese dat MBL dysfunctie een rol kan
spelen bij de ontwikkeling en het beloop van SLE, hetgeen mogelijk verklaard kan
worden door een verminderd opruimen van apoptotisch materiaal en daardoor een
verhoogde productie van autoantistoffen. 
Conclusie
Een beschermende rol van de MBL-route van complement activatie, door middel van
het opruimen van apoptotisch materiaal, lijkt waarschijnlijk gezien de verminderde
aanwezigheid  van autoantistoffen in patienten met een goede MBL functie. Echter,
activatie van de MBL-route kan ook tot verergering van orgaanschade leiden.
Daarnaast kan de complementactiverende functie van het MBL verminderd worden
door de autoantistoffen gericht tegen MBL. Deze autoantistoffen worden  in het serum
van patienten met SLE gevonden.
Voor patiënten bij wie een immuundeficiëntie wordt vermoed, is het vaststellen van
een mogelijke complementdeficiëntie van belang voor het stellen van een diagnose.
Bovendien kan de mate van complementactivatie van belang zijn om de ziekteactivi-
teit te vervolgen en de effectiviteit van de behandeling te evalueren. De functionele
activiteit van de complementeactivatieroutes wordt, voor de klassieke en de alternatie-
ve route, bepaald door het meten van  complementafhankelijke lysis van erythrocyten. 
Er is recent een methode ontwikkeld om de activiteit van alle drie de routes te bepa-
len door middel van ELISA. Met behulp van voor iedere route specifieke activatoren
en condities wordt selectief de activiteit van elke route gemeten. De uiteindelijke vor-
ming van het "membrane attack complex" (C5b-9) bepaalt de mate van activiteit van
één van de routes.
Met deze methode is het voor het eerst mogelijk om de activiteit van de hele MBL-
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route in serum te bepalen en om tegelijkertijd de klassieke en de alternatieve routeac-
tiviteit op eenvoudige wijze te meten. De resultaten van het onderzoek, uitgevoerd
binnen een Europese samenwerking, omtrent de verschillen in functionele activiteit
van de complementroutes tussen mannen en vrouwen én de verandering hiervan met
toename van de leeftijd, zijn in dit proefschrift beschreven.
Hoofdstuk 5. Standaardisering en validatie van een nieuwe methode om
de functionele activiteit van complementroutes  te meten.
Om de toepasbaarheid van deze nieuwe meetmethode te testen is de activatie van de
drie verschillende routes gemeten in 120 sera van gezonden individuen. Deze bepalin-
gen zijn gedaan in drie verschillende laboratoria in Europa. Dit onderzoek heeft laten
zien dat de meetmethode goed vergelijkbaar is tussen verschillende laboratoria. Met
behulp van de testuitslagen werd voor elk van de drie routes de ondergrens van nor-
male routeactiviteit vastgesteld. Om de bruikbaarheid van de meetmethode te testen
voor het detecteren van complementdeficiënties werden sera met al eerder vastgestel-
de erfelijke deficiënties getest. Op deze manier werd aangetoond dat deze methode
goed bruikbaar is om sera te screenen voor aangeboren complementdeficiënties. Ook
werd er aangetoond  dat deze meetmethode bruikbaar is om complementconsumptie
vast te stellen in sera van patiënten met verschillenden ziekten waarvan bekend is dat
er complementverbruik plaatsvindt. Met deze nieuwe meetmethode is het mogelijk
geworden om de drie routes van het complementsysteem te screenen op deficiënties
en ook om complementverbruik vast te stellen.
Hoofdstuk 6. Verschil in de functionele activiteit van complementactivatieroutes
tussen mannen en vrouwen en de verandering hiervan met het toenemen van de
leeftijd.
Veel aandacht is er besteed aan de veranderingen in complementactivatie bij jonge kin-
deren.  Bij jonge kinderen is de afweer tegen microorganismen, na  de periode van de
beschermende antistoffen van de moeder, afhankelijk van een goed functionerend aan-
geboren afweersysteem. Ook op oudere leeftijd, wanneer de verworven immuniteit
minder wordt, zou het aangeboren afweersysteem een belangrijke rol kunnen spelen.
Echter, het cellulaire deel van de aangeboren afweer neemt in functie af met het toene-
men van de leeftijd. Leeftijdsafhankelijke veranderingen in complementactiviteit,
zoals in dit onderzoek beschreven, werden eerder nauwelijks onderzocht. 
De resultaten van deze studie laten een significante toename zien van de klassieke en
alternatieve routeactiviteit met het toenemen van de leeftijd. Deze toename in routeac-
tiviteit zou een manier kunnen zijn waardoor de afgenomen immuniteit bij ouderen
gecompenseerd kan worden. Echter, een afname van de MBL route werd gevonden bij
toename van de leeftijd. Een mogelijk voordeel van afname van MBL routeactiviteit
zou het ongunstig effect van MBL op vaatschade kunnen zijn. In overeenstemming
met de klassieke routeactiviteit werd er een toename van de C2 concentratie gevonden;
voor de alternatieve route werd er een toename van factor B concentratie gevonden.
De lagere MBL routeactiviteit was sterk gecorreleerd met afgenomen MBL serumcon-
centraties. In vergelijking met mannen, werd er bij vrouwen een lagere alternatieve
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routeactiviteit gevonden. Lagere C3 concentratie in het serum bij vrouwen zou moge-
lijk een verklaring kunnen zijn voor de verminderde alternatieve route activiteit. 
In de studie wordt een toegenomen activiteit van het aangeboren afweersysteem
gevonden voor de klassieke route en alternatieve route met het ouder worden.
Daarentegen werd een afgenomen MBL route activiteit vastgesteld bij ouderen. Het
verschil in incidentie van sommige (auto-) immuunziekten tussen mannen en vrou-
wen kan mogelijk deels verklaard kan worden door het verschil in functionele activi-
teit van de complementroutes. 
Conclusie
De klassieke route en alternatieve route van  het complementsysteem nemen  in func-
tionele activiteit toe met toename van leeftijd, hetgeen van belang kan zijn in de
bescherming tegen infectieziekten bij ouderen, bij wie de verworven immuniteit afge-
nomen is. Het verschil in functionele activiteit van het complementsysteem tussen
mannen en vrouwen speelt mogelijk een rol in het verschil van voorkomen van (auto-
) immuunziekten in  beide geslachten.
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